| 1 |
Matchett CL, Simonetto DA, Kamath PS. Renal Insufficiency in Patients with Cirrhosis. Clin Liver Dis 2023;27:57-70. [PMID: 36400467 DOI: 10.1016/j.cld.2022.08.010] [Reference Citation Analysis]
|
| 2 |
Wong F. Hepatorenal syndrome and acute kidney injury in cirrhosis. Cardio-Hepatology 2023. [DOI: 10.1016/b978-0-12-817394-7.00003-6] [Reference Citation Analysis]
|
| 3 |
Li X, Yuan F, Zhou L. Organ Crosstalk in Acute Kidney Injury: Evidence and Mechanisms. J Clin Med 2022;11. [PMID: 36431113 DOI: 10.3390/jcm11226637] [Reference Citation Analysis]
|
| 4 |
Singal AK, Kuo YF, Reddy KR, Bataller R, Kwo P. Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US. Aliment Pharmacol Ther 2022;56:1486-96. [PMID: 36196562 DOI: 10.1111/apt.17232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Bai Z, Wang L, Lin H, Tacke F, Cheng G, Qi X. Use of Human Albumin Administration for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis. JCM 2022;11:5928. [DOI: 10.3390/jcm11195928] [Reference Citation Analysis]
|
| 6 |
Wakil A, Mohamed M, Tafesh Z, Niazi M, Olivo R, Xia W, Greenberg P, Pyrsopoulos N. Trends in hospitalization for alcoholic hepatitis from 2011 to 2017: A USA nationwide study. World J Gastroenterol 2022; 28(34): 5036-5046 [DOI: 10.3748/wjg.v28.i34.5036] [Reference Citation Analysis]
|
| 7 |
Yang C, Xiong B. A comprehensive review of prognostic scoring systems to predict survival after transjugular intrahepatic portosystemic shunt placement. Portal Hypertension & Cirrhosis 2022;1:133-144. [DOI: 10.1002/poh2.28] [Reference Citation Analysis]
|
| 8 |
Zheng F, Ye X, Chen Y, Wang H, Fang S, Shi X, Lin Z, Lin Z. Treatment of hyponatremia in children with acute bacterial meningitis. Front Neurol 2022;13:911784. [DOI: 10.3389/fneur.2022.911784] [Reference Citation Analysis]
|
| 9 |
Ponzo P, Campion D, Rizzo M, Roma M, Caviglia GP, Giovo I, Rizzi F, Bonetto S, Saracco GM, Alessandria C. Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. Dig Liver Dis 2022;54:1101-8. [PMID: 34625366 DOI: 10.1016/j.dld.2021.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Habas E, Ibrahim AR, Moursi MO, Shraim BA, Elgamal ME, Elzouki AN. Update on hepatorenal Syndrome: Definition, Pathogenesis, and management. Arab J Gastroenterol 2022:S1687-1979(22)00005-3. [PMID: 35473682 DOI: 10.1016/j.ajg.2022.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Shweta K, Neelima C, Madhuri K. Study of Clinical Profile and Outcome in Patients of Alcohol Induced Chronic Liver Disease with Hepato Renal Syndrome. MVP J M S 2022. [DOI: 10.18311/mvpjms/2021/v8i2/307] [Reference Citation Analysis]
|
| 12 |
Wang X, Jamil K. Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome. AAPS Open 2022;8. [DOI: 10.1186/s41120-022-00052-7] [Reference Citation Analysis]
|
| 13 |
Ubrangala RK, Ravishankar A. STUDY OF RENAL RESISTIVITY INDEX IN LIVER CIRRHOSIS IN PREDICTING THE INCIDENCE OF HEPATORENAL SYNDROME. PIJR 2022. [DOI: 10.36106/paripex/7907344] [Reference Citation Analysis]
|
| 14 |
Praharaj DL, Anand AC. Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis. J Clin Exp Hepatol 2022;12:575-94. [PMID: 35535075 DOI: 10.1016/j.jceh.2021.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 15 |
Terres AZ, Balbinot RS, Muscope ALF, Longen ML, Schena B, Cini BT, Luis Rost G, Balensiefer JIL, Eberhardt LZ, Balbinot RA, Balbinot SS, Soldera J. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterología y Hepatología (English Edition) 2022;45:25-39. [DOI: 10.1016/j.gastre.2021.02.009] [Reference Citation Analysis]
|
| 16 |
O’riordan A, Ware T. Hepatology and the Kidney. Primer on Nephrology 2022. [DOI: 10.1007/978-3-030-76419-7_36] [Reference Citation Analysis]
|
| 17 |
Zgheib NK, Lertora JJ, Branch RA. Effect of liver disease on pharmacokinetics. Atkinson's Principles of Clinical Pharmacology 2022. [DOI: 10.1016/b978-0-12-819869-8.00005-7] [Reference Citation Analysis]
|
| 18 |
Al-jedai A, Alabdulkarim Z, Alkortas D, Alsebayel M, Alkhail F, Elsiesy H. Efficacy and predictors to response of octreotide and midodrine combination in patients with hepatorenal syndrome. Saudi J Clin Pharm 2022;1:69. [DOI: 10.4103/sjcp.sjcp_4_22] [Reference Citation Analysis]
|
| 19 |
Kozich EA, Krasavtsev EL. Predictors of the development of hepatorenal syndrome. jour 2021;18:69-73. [DOI: 10.51523/2708-6011.2021-18-4-9] [Reference Citation Analysis]
|
| 20 |
Liu S, Meng Q, Xu Y, Zhou J. Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion. Gastroenterol Rep (Oxf) 2021;9:505-20. [PMID: 34925848 DOI: 10.1093/gastro/goab040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 21 |
Sasso R, Abou Yassine A, Deeb L. Predictors of Development of Hepatorenal Syndrome in Hospitalized Cirrhotic Patients with Acute Kidney Injury. J Clin Med 2021;10:5621. [PMID: 34884323 DOI: 10.3390/jcm10235621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 22 |
Hieu TH, Hashan MR, Morsy S, Tawfik GM, Cucè F, Sharma A, Quynh TTH, Faraj HA, Qarawi ATA, Huy NT. Hyponatremia in tuberculous meningitis: A systematic review and meta-analysis. Indian J Tuberc 2021;68:516-26. [PMID: 34752323 DOI: 10.1016/j.ijtb.2021.06.004] [Reference Citation Analysis]
|
| 23 |
Chaney A. A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis. Clin Exp Gastroenterol 2021;14:385-96. [PMID: 34675586 DOI: 10.2147/CEG.S323778] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 24 |
Sheng X, Chen W, Xu Y, Lin F, Cao H. Higher Mean Corpuscular Hemoglobin Concentration is Associated with Worse Prognosis of Hepatorenal Syndrome: A Multicenter Retrospective Study. Am J Med Sci 2021:S0002-9629(21)00356-6. [PMID: 34624233 DOI: 10.1016/j.amjms.2021.06.026] [Reference Citation Analysis]
|
| 25 |
Polyak A, Kuo A, Sundaram V. Evolution of liver transplant organ allocation policy: Current limitations and future directions. World J Hepatol 2021; 13(8): 830-839 [PMID: 34552690 DOI: 10.4254/wjh.v13.i8.830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 26 |
Su WY, Chu NS, Huang JC, Wu PY, Lee WH, Liu YH, Chen SC, Su HM. Low Albumin, Low Bilirubin, and High Alfa-Fetoprotein Are Associated with a Rapid Renal Function Decline in a Large Population Follow-Up Study. J Pers Med 2021;11:781. [PMID: 34442425 DOI: 10.3390/jpm11080781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 27 |
Flamm SL, Brown K, Wadei HM, Brown RS Jr, Kugelmas M, Samaniego-Picota M, Burra P, Poordad F, Saab S. The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin. Liver Transpl 2021;27:1191-202. [PMID: 33848394 DOI: 10.1002/lt.26072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 28 |
Sangroongruangsri S, Kittrongsiri K, Charatcharoenwitthaya P, Sobhonslidsuk A, Chaikledkaew U. Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome. Clinicoecon Outcomes Res 2021;13:703-15. [PMID: 34349534 DOI: 10.2147/CEOR.S317390] [Reference Citation Analysis]
|
| 29 |
Koshy AN, Farouque O, Cailes B, Ko J, Han HC, Weinberg L, Testro A, Robertson M, Teh AW, Lim HS, Gow PJ. Prediction of Perioperative Cardiovascular Events in Liver Transplantation. Transplantation 2021;105:593-601. [PMID: 32413014 DOI: 10.1097/TP.0000000000003306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 30 |
Torres-vellojín N, Díaz-duque JC, Toro-molina JL, Muñoz-maya OG. Disfunción renal en el paciente cirrótico. Hepatología 2021. [DOI: 10.52784/27112330.136] [Reference Citation Analysis]
|
| 31 |
Subedi A, Suresh Kumar VC, Sharma Subedi A, Sapkota B. A Review of Hepatorenal Syndrome. Cureus 2021;13:e16084. [PMID: 34367745 DOI: 10.7759/cureus.16084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 32 |
Makar M, Reja D, Chouthai A, Kabaria S, Patel AV. The impact of acute kidney injury on mortality and clinical outcomes in patients with alcoholic cirrhosis in the USA. Eur J Gastroenterol Hepatol 2021;33:905-10. [PMID: 32976187 DOI: 10.1097/MEG.0000000000001947] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 33 |
Mauro E, Garcia-Olveira L, Gadano A. End-stage liver disease: Management of hepatorenal syndrome. Liver Int 2021;41 Suppl 1:119-27. [PMID: 34155791 DOI: 10.1111/liv.14866] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 34 |
Wang YJ, Li JH, Guan Y, Xie QH, Hao CM, Wang ZX. Diabetes mellitus is a risk factor of acute kidney injury in liver transplantation patients. Hepatobiliary Pancreat Dis Int 2021;20:215-21. [PMID: 33752999 DOI: 10.1016/j.hbpd.2021.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 35 |
Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 36 |
Thongprayoon C, Kaewput W, Petnak T, O'Corragain OA, Boonpheng B, Bathini T, Vallabhajosyula S, Pattharanitima P, Lertjitbanjong P, Qureshi F, Cheungpasitporn W. Impact of Palliative Care Services on Treatment and Resource Utilization for Hepatorenal Syndrome in the United States. Medicines (Basel) 2021;8:21. [PMID: 34065828 DOI: 10.3390/medicines8050021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 37 |
Terres AZ, Balbinot RS, Muscope ALF, Longen ML, Schena B, Cini BT, Luis Rost G Jr, Balensiefer JIL, Eberhardt LZ, Balbinot RA, Balbinot SS, Soldera J. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterol Hepatol 2021:S0210-5705(21)00086-8. [PMID: 33746028 DOI: 10.1016/j.gastrohep.2021.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 38 |
Kubesch A, Peiffer KH, Abramowski H, Dultz G, Graf C, Filmann N, Zeuzem S, Bojunga J, Friedrich-Rust M. The presence of liver cirrhosis is a strong negative predictor of survival for patients admitted to the intensive care unit - Cirrhosis in intensive care patients. Z Gastroenterol 2021;59:657-64. [PMID: 33728617 DOI: 10.1055/a-1401-2387] [Reference Citation Analysis]
|
| 39 |
McAllister S, Lai JC, Copeland TP, Johansen KL, McCulloch CE, Kwong YD, Seth D, Grimes B, Ku E. Renal Recovery and Mortality Risk among Patients with Hepatorenal Syndrome Receiving Chronic Maintenance Dialysis. Kidney360 2021;2:819-27. [PMID: 35373067 DOI: 10.34067/KID.0005182020] [Reference Citation Analysis]
|
| 40 |
Singh J, Dahiya DS, Kichloo A, Singh G, Khoshbin K, Shaka H. Hepatorenal syndrome: a Nationwide Trend Analysis from 2008 to 2018. Annals of Medicine 2021;53:2018-2024. [DOI: 10.1080/07853890.2021.1998595] [Reference Citation Analysis]
|
| 41 |
Rajakumar A, Appuswamy E, Kaliamoorthy I, Rela M. Renal Dysfunction in Cirrhosis: Critical Care Management. Indian J Crit Care Med 2021;25:207-14. [PMID: 33707901 DOI: 10.5005/jp-journals-10071-23721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 42 |
Hiruy A, Nelson J, Zori A, Morelli G, Cabrera R, Kamel A. Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate. Eur J Gastroenterol Hepatol 2021;33:102-6. [PMID: 32243349 DOI: 10.1097/MEG.0000000000001700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 43 |
Gallo A, Dedionigi C, Civitelli C, Panzeri A, Corradi C, Squizzato A. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. J Transl Int Med 2020;8:220-36. [PMID: 33511049 DOI: 10.2478/jtim-2020-0035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 44 |
Hyun J, Sun Z, Ahmadi AR, Bangru S, Chembazhi UV, Du K, Chen T, Tsukamoto H, Rusyn I, Kalsotra A, Diehl AM. Epithelial splicing regulatory protein 2-mediated alternative splicing reprograms hepatocytes in severe alcoholic hepatitis. J Clin Invest 2020;130:2129-45. [PMID: 31945016 DOI: 10.1172/JCI132691] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 45 |
Velez JCQ. Patients with Hepatorenal Syndrome Should Be Dialyzed? PRO. Kidney360 2021;2:406-9. [PMID: 35369012 DOI: 10.34067/KID.0006952020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 46 |
Theodorakopoulos T, Kalafateli M, Kalambokis GN, Samonakis DN, Aggeletopoulou I, Tsolias C, Mantaka A, Tselekouni P, Vourli G, Assimakopoulos SF, Gogos C, Thomopoulos K, Milionis H, Triantos C. Natural history of grade 1 ascites in patients with liver cirrhosis. Ann Gastroenterol 2021;34:93-103. [PMID: 33414628 DOI: 10.20524/aog.2020.0553] [Reference Citation Analysis]
|
| 47 |
Allegretti AS, Solà E, Ginès P. Clinical Application of Kidney Biomarkers in Cirrhosis. American Journal of Kidney Diseases 2020;76:710-9. [DOI: 10.1053/j.ajkd.2020.03.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 48 |
Alukal JJ, John S, Thuluvath PJ. Hyponatremia in Cirrhosis: An Update. Am J Gastroenterol 2020;115:1775-85. [PMID: 33156095 DOI: 10.14309/ajg.0000000000000786] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 49 |
Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2650-66. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 278] [Cited by in F6Publishing: 242] [Article Influence: 92.7] [Reference Citation Analysis]
|
| 50 |
Rey R M, Delgado AF, De Zubiria A, Pinto R, De la Hoz-Valle JA, Pérez-Riveros ED, Ardila G, Sierra-Arango F. Prevalence and short-term outcome of hepatorenal syndrome: A 9-year experience in a high-complexity hospital in Colombia. PLoS One 2020;15:e0239834. [PMID: 33079947 DOI: 10.1371/journal.pone.0239834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 51 |
Liu PMF, de Carvalho ST, Fradico PF, Cazumbá MLB, Campos RGB, Simões E Silva AC. Hepatorenal syndrome in children: a review. Pediatr Nephrol 2021;36:2203-15. [PMID: 33001296 DOI: 10.1007/s00467-020-04762-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 52 |
Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management.BMJ. 2020;370:m2687. [PMID: 32928750 DOI: 10.1136/bmj.m2687] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 19.3] [Reference Citation Analysis]
|
| 53 |
Wu PS, Wang YW, Tai CC, Hsieh YC, Lee PC, Huang CC, Huang YH, Hou MC, Lin HC, Lee KC. Early echocardiographic signs of diastolic dysfunction predict acute kidney injury in cirrhotic patients. J Chin Med Assoc 2020;83:984-90. [PMID: 32889984 DOI: 10.1097/JCMA.0000000000000422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 54 |
Smith RE, Friedman AD, Murchison JA, Tanner SB, Smith PA, Dollar BT. Acute Life-Threatening Complications of Portal Hypertension: a Review of Pathophysiology, Incidence, Management, and Cost. SN Compr Clin Med 2020;2:1628-1645. [DOI: 10.1007/s42399-020-00435-5] [Reference Citation Analysis]
|
| 55 |
Fida S, Khurshid SMS, Mansoor H. Frequency of Hepatorenal Syndrome Among Patients With Cirrhosis and Outcome After Treatment. Cureus 2020;12:e10016. [PMID: 32983712 DOI: 10.7759/cureus.10016] [Reference Citation Analysis]
|
| 56 |
Tariq R, Singal AK. Management of Hepatorenal Syndrome: A Review. J Clin Transl Hepatol 2020;8:192-9. [PMID: 32832400 DOI: 10.14218/JCTH.2020.00011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 57 |
Wu YH, Wu CY, Cheng CY, Tsai SF. Severe hyperbilirubinemia is associated with higher risk of contrast-related acute kidney injury following contrast-enhanced computed tomography. PLoS One 2020;15:e0231264. [PMID: 32294106 DOI: 10.1371/journal.pone.0231264] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 58 |
Trivedi PS, Brown MA, Rochon PJ, Ryu RK, Johnson DT. Gender Disparity in Inpatient Mortality After Transjugular Intrahepatic Portosystemic Shunt Creation in Patients Admitted With Hepatorenal Syndrome: A Nationwide Study. Journal of the American College of Radiology 2020;17:231-7. [DOI: 10.1016/j.jacr.2019.08.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 59 |
Zimmerman MA, Schiller J, Selim M, Kim J, Hong JC. Management of Renal Failure in the Liver Transplant Patient. Curr Transpl Rep 2019;6:338-343. [DOI: 10.1007/s40472-019-00259-w] [Reference Citation Analysis]
|
| 60 |
Facciorusso A. Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects.Ther Clin Risk Manag. 2019;15:1383-1391. [PMID: 31819465 DOI: 10.2147/TCRM.S205328] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 61 |
Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.Nat Rev Nephrol. 2020;16:137-155. [PMID: 31723234 DOI: 10.1038/s41581-019-0218-4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 62 |
Hermert D, Martin IV, Reiss LK, Liu X, Breitkopf DM, Reimer KC, Alidousty C, Rauen T, Floege J, Ostendorf T, Weiskirchen R, Raffetseder U. The nucleic acid binding protein YB-1-controlled expression of CXCL-1 modulates kidney damage in liver fibrosis. Kidney Int 2020;97:741-52. [PMID: 32061437 DOI: 10.1016/j.kint.2019.10.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 63 |
Adebayo D, Neong SF, Wong F. Ascites and Hepatorenal Syndrome. Clin Liver Dis 2019;23:659-82. [PMID: 31563217 DOI: 10.1016/j.cld.2019.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 64 |
Barnes A, Woodman RJ, Kleinig P, Briffa M, To T, Wigg AJ. Early palliative care referral in patients with end stage liver disease is associated with reduced resource utilisation. J Gastroenterol Hepatol 2019. [PMID: 31613397 DOI: 10.1111/jgh.14877] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 65 |
Wang L, Long Y, Li KX, Xu GS. Pharmacological treatment of hepatorenal syndrome: a network meta-analysis.Gastroenterol Rep (Oxf). 2020;8:111-118. [PMID: 32280470 DOI: 10.1093/gastro/goz043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 66 |
Schiavon LL, Ejima FH, Menezes MR, Bittencourt PL, Moreira AM, Farias AQ, Chagas AL, Assis AM, Mattos ÂZ, Salomão BC, Terra C, Martins FPB, Carnevale FC, Rezende GFDM, Paulo GA, Pereira GHS, Leal Filho JMDM, Meneses J, Costa LSND, Carneiro MV, Álvares-DA-Silva MR, Soares MVA, Pereira OI, Ximenes RO, Durante RFS, Ferreira VA, Lima VM; Members of the Pannel of the 1st Joint Meeting of the SBH, SOBED and SOBRICE. RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). Arq Gastroenterol 2019;56:213-31. [PMID: 31460590 DOI: 10.1590/S0004-2803.201900000-42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 67 |
Koola JD, Chen G, Malin BA, Fabbri D, Siew ED, Ho SB, Patterson OV, Matheny ME. A clinical risk prediction model to identify patients with hepatorenal syndrome at hospital admission. Int J Clin Pract. 2019;73:e13393. [PMID: 31347754 DOI: 10.1111/ijcp.13393] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 68 |
Bhatti HW, Tahir U, Chaudhary NA, Bhatti S, Hafeez M, Rizvi ZA. Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score. BMJ Open Gastroenterol 2019;6:e000286. [PMID: 31275583 DOI: 10.1136/bmjgast-2019-000286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 69 |
Runken MC, Caraceni P, Fernandez J, Zipprich A, Carlton R, Bunke M. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain. Health Econ Rev 2019;9:22. [PMID: 31278624 DOI: 10.1186/s13561-019-0237-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 70 |
Nevens F, Bittencourt PL, Coenraad MJ, Ding H, Hou MC, Laterre PF, Mendizabal M, Ortiz-Olvera NX, Vorobioff JD, Zhang W, Angeli P. Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. Dig Dis Sci 2019;64:1419-31. [PMID: 30684079 DOI: 10.1007/s10620-018-5448-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 71 |
Francoz C, Sola E. Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter. J Hepatol 2019;70:828-30. [PMID: 30833013 DOI: 10.1016/j.jhep.2019.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 72 |
Attar B. Approach to Hyponatremia in Cirrhosis. Clin Liver Dis (Hoboken) 2019;13:98-101. [PMID: 31061701 DOI: 10.1002/cld.790] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 73 |
Varajic B, Cavallazzi R, Mann J, Furmanek S, Guardiola J, Saad M. High versus low mean arterial pressures in hepatorenal syndrome: A randomized controlled pilot trial. J Crit Care 2019;52:186-92. [PMID: 31096099 DOI: 10.1016/j.jcrc.2019.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 74 |
Shenoda B, Boselli J. Vascular syndromes in liver cirrhosis. Clin J Gastroenterol 2019;12:387-97. [PMID: 30980261 DOI: 10.1007/s12328-019-00956-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 75 |
Dong V, Karvellas CJ. Acute-on-chronic liver failure: Objective admission and support criteria in the intensive care unit. JHEP Rep 2019;1:44-52. [PMID: 32039351 DOI: 10.1016/j.jhepr.2019.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 76 |
Jamil K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G. The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. J Med Econ 2019;22:421-9. [PMID: 30724682 DOI: 10.1080/13696998.2019.1580201] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 77 |
Xu J, Xia Y, Li S, Cheng X, Hu S, Gao Y, Zhou X, Wang G, Zheng Q. A retrospective pilot study to examine the potential of aspartate aminotransferase to alanine aminotransferase ratio as a predictor of postoperative acute kidney injury in patients with hepatocellular carcinoma. Ann Clin Biochem 2019;56:357-66. [PMID: 30453754 DOI: 10.1177/0004563218817797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 78 |
Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterol J 2019;7:529-37. [PMID: 31065370 DOI: 10.1177/2050640619825719] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 79 |
Myers SP, Kulkarni SS, Malik SM, Tevar AD, Neal MD. Hernia Management in Cirrhosis: Risk Assessment, Operative Approach, and Perioperative Care. J Surg Res 2019;235:1-7. [PMID: 30691782 DOI: 10.1016/j.jss.2018.09.052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 80 |
Piano S, Tonon M, Angeli P. Pathophysiology and Management of the Hepatorenal Syndrome. Critical Care Nephrology 2019. [DOI: 10.1016/b978-0-323-44942-7.00128-x] [Reference Citation Analysis]
|
| 81 |
Piano S, Angeli P. Acute Kidney Injury and Hepatorenal Syndrome. Critical Care for Potential Liver Transplant Candidates 2019. [DOI: 10.1007/978-3-319-92934-7_9] [Reference Citation Analysis]
|
| 82 |
Ando Y, Ahn J. Hepatorenal Syndrome. Liver Disease 2019. [DOI: 10.1007/978-3-319-98506-0_5] [Reference Citation Analysis]
|
| 83 |
Song J, Zhu L, Zhu C, Hu J, Sun Z, Xu X, Xin M, Zhang Q, Zhang D, Shang J, Huang J, Xu D. Main Complications of AECHB and Severe Hepatitis B (Liver Failure). Acute Exacerbation of Chronic Hepatitis B 2019. [DOI: 10.1007/978-94-024-1603-9_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 84 |
Myers SP, Malik SM, Tevar AD, Neal MD. Herniorrhaphy in Cirrhosis: Operative Approach and Timing. The SAGES Manual of Hernia Surgery 2019. [DOI: 10.1007/978-3-319-78411-3_47] [Reference Citation Analysis]
|
| 85 |
Yang SM, Choi SN, Yu JH, Yoon HK, Kim WH, Jung CW, Suh KS, Lee KH. Intraoperative hyponatremia is an independent predictor of one-year mortality after liver transplantation. Sci Rep 2018;8:18023. [PMID: 30575797 DOI: 10.1038/s41598-018-37006-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 86 |
Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol 2019;13:293-305. [PMID: 30791777 DOI: 10.1080/17474124.2018.1555469] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 87 |
Leise M, Cárdenas A. Hyponatremia in Cirrhosis: Implications for Liver Transplantation. Liver Transpl 2018;24:1612-21. [PMID: 30129266 DOI: 10.1002/lt.25327] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 88 |
Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol 2018;11:1756284818800307. [PMID: 30283499 DOI: 10.1177/1756284818800307] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 89 |
Bernardi M, Zaccherini G. Approach and management of dysnatremias in cirrhosis. Hepatol Int. 2018;12:487-499. [PMID: 30203382 DOI: 10.1007/s12072-018-9894-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 90 |
Terra C, Mattos ÂZD, Pereira G, Farias AQ, Kondo M, Mattos AAD, Medeiros Filho JEMD, Strauss E, Dutra FRD, Mazza M, Lopes EP, Pereira TS, Schiavon LL, Carvalho Filho RJD, Fagundes C, Bittencourt PL. RECOMMENDATIONS OF THE BRAZILIAN SOCIETY OF HEPATOLOGY FOR THE MANAGEMENT OF ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS. Arq Gastroenterol 2018;55:314-20. [DOI: 10.1590/s0004-2803.201800000-71] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 91 |
Weinmann-menke J, Weinmann A, Lutz J. Hepatorenales Syndrom. Nephrologe 2018;13:277-289. [DOI: 10.1007/s11560-018-0264-0] [Reference Citation Analysis]
|
| 92 |
Garcia-tsao G. Ascites. Sherlock's Diseases of the Liver and Biliary System 2018. [DOI: 10.1002/9781119237662.ch9] [Reference Citation Analysis]
|
| 93 |
Kalambokis GN, Tsiakas I, Christaki M, Koustousi C, Christou L, Baltayiannis G, Christodoulou D. Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis. Eur J Gastroenterol Hepatol 2018;30:659-67. [PMID: 29432366 DOI: 10.1097/MEG.0000000000001088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 94 |
Shetty S, Nagaraju SP, Shenoy S, Attur RP, Rangaswamy D, Rao IR, Mateti UV, Parthasarathy R. Acute kidney injury in patients with cirrhosis of liver: Clinical profile and predictors of outcome. Indian J Gastroenterol 2018;37:248-54. [PMID: 30014435 DOI: 10.1007/s12664-018-0867-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 95 |
Koola JD, Davis SE, Al-Nimri O, Parr SK, Fabbri D, Malin BA, Ho SB, Matheny ME. Development of an automated phenotyping algorithm for hepatorenal syndrome. J Biomed Inform 2018;80:87-95. [PMID: 29530803 DOI: 10.1016/j.jbi.2018.03.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 96 |
Said MM, Azab SS, Saeed NM, El-Demerdash E. Antifibrotic Mechanism of Pinocembrin: Impact on Oxidative Stress, Inflammation and TGF-β /Smad Inhibition in Rats. Ann Hepatol 2018;17:307-17. [PMID: 29469035 DOI: 10.5604/01.3001.0010.8661] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 97 |
Stine JG, Wang J, Cornella SL, Behm BW, Henry Z, Shah NL, Caldwell SH, Northup PG. Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial. Ann Hepatol 2018;17:300-6. [PMID: 29469046 DOI: 10.5604/01.3001.0010.8660] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 98 |
Kramer L, Bauer E, Gendo A, Madl C, Gangl A. Influence of Hydroxy Ethyl Starch Infusion on Serum Bilirubin Levels in Cirrhotic Patients Treated with Artificial Liver Support. Int J Artif Organs 2002;25:918-22. [DOI: 10.1177/039139880202501004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 99 |
Chen Y, Wu Z, He J, Yu J, Yang S, Zhang Y, Du W, Cao H, Li L. The Curative Effect of ALSS on 1-month Mortality in AoCLF Patients after 72 to 120 Hours. Int J Artif Organs 2007;30:906-14. [DOI: 10.1177/039139880703001008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 100 |
Fabrizi F, Dixit V, Messa P, Martin P. Terlipressin for Hepatorenal Syndrome: A Meta-Analysis of Randomized Trials. Int J Artif Organs 2009;32:133-40. [DOI: 10.1177/039139880903200303] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 101 |
Diaz GC, Chow J, Renz JF. Combined Solid Organ Transplantation Involving the Liver. Liver Anesthesiology and Critical Care Medicine 2018. [DOI: 10.1007/978-3-319-64298-7_19] [Reference Citation Analysis]
|
| 102 |
Berl T, Schrier RW. Vasopressin Antagonists in Physiology and Disease. Textbook of Nephro-Endocrinology 2018. [DOI: 10.1016/b978-0-12-803247-3.00007-6] [Reference Citation Analysis]
|
| 103 |
Belcher JM, Parikh CR. Acute Kidney Injury and Liver Disease: Incidence, Pathophysiology, Prevention/Treatment, and Outcomes. Core Concepts in Acute Kidney Injury 2018. [DOI: 10.1007/978-1-4939-8628-6_7] [Reference Citation Analysis]
|
| 104 |
Colle I, Laterre PF. Hepatorenal syndrome: the clinical impact of vasoactive therapy. Expert Rev Gastroenterol Hepatol. 2018;12:173-188. [PMID: 29258378 DOI: 10.1080/17474124.2018.1417034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 105 |
Majc D, Tepes B. The Impact of Outpatient Clinical Care on the Survival and Hospitalisation Rate in Patients with Alcoholic Liver Cirrhosis. Radiol Oncol 2018;52:75-82. [PMID: 29520208 DOI: 10.1515/raon-2017-0056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 106 |
Kamal F, Khan MA, Khan Z, Cholankeril G, Hammad TA, Lee WM, Ahmed A, Waters B, Howden CW, Nair S, Satapathy SK. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:1109-17. [PMID: 28763340 DOI: 10.1097/MEG.0000000000000940] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 107 |
Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL. Terlipressin vs other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9:CD011532. [PMID: 28953318 DOI: 10.1002/14651858.cd011532.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 108 |
Sridharan K, Sivaramakrishnan G. Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials. J Gen Intern Med. 2018;33:97-102. [PMID: 28924736 DOI: 10.1007/s11606-017-4178-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 109 |
Scheiner B, Parada-Rodriguez D, Bucsics T, Schwabl P, Mandorfer M, Pfisterer N, Riedl F, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scand J Gastroenterol 2017;52:1008-15. [PMID: 28532189 DOI: 10.1080/00365521.2017.1329456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 110 |
Singh N, Ahmadzadeh S, Shokouh-Amiri H, Qazi YA, Sequeira A, Samant H, McMillan R, Zibari GB. Kidney outcomes in patients with liver cirrhosis and chronic kidney disease receiving an orthotopic liver transplant alone. Clin Transplant. 2017;31. [PMID: 28504869 DOI: 10.1111/ctr.13008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 111 |
Allegretti AS, Israelsen M, Krag A, Jovani M, Goldin AH, Schulman AR, Winter RW, Gluud LL. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. Cochrane Database Syst Rev 2017;6:CD005162. [PMID: 29943803 DOI: 10.1002/14651858.CD005162.pub4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 112 |
Flechner SM. Simultaneous Liver-Kidney Transplantation: What are Our Obligations to the Kidney Only Recipient? Curr Transpl Rep 2017;4:110-5. [DOI: 10.1007/s40472-017-0150-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 113 |
Kao CC, Yang JY, Chen L, Chao CT, Peng YS, Chiang CK, Huang JW, Hung KY. Factors associated with poor outcomes of continuous renal replacement therapy. PLoS One. 2017;12:e0177759. [PMID: 28542272 DOI: 10.1371/journal.pone.0177759] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 114 |
Foshat M, Ruff HM, Fischer WG, Beach RE, Fowler MR, Ju H, Aronson JF, Afrouzian M. Bile Cast Nephropathy in Cirrhotic Patients: Effects of Chronic Hyperbilirubinemia. Am J Clin Pathol 2017;147:525-35. [PMID: 28398539 DOI: 10.1093/ajcp/aqx030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 115 |
Fabrizi F, Messa P. Challenges in Renal Failure Treatment Before Liver Transplant. Clin Liver Dis 2017;21:303-19. [PMID: 28364815 DOI: 10.1016/j.cld.2016.12.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 116 |
Altaf. Determine the Frequency of Hepatorenal Syndrome in Patients with Cirrhosis Associated With Hepatitis C. ICPJL 2017;4. [DOI: 10.15406/icpjl.2017.04.00105] [Reference Citation Analysis]
|
| 117 |
Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5:127-137. [PMID: 28533910 DOI: 10.1093/gastro/gox009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 118 |
Walayat S, Martin D, Patel J, Ahmed U, N Asghar M, Pai AU, Dhillon S. Role of albumin in cirrhosis: from a hospitalist's perspective. J Community Hosp Intern Med Perspect. 2017;7:8-14. [PMID: 28634518 DOI: 10.1080/20009666.2017.1302704] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 119 |
Yap DY, Seto WK, Fung J, Chok SH, Chan SC, Chan GC, Yuen MF, Chan TM. Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. Dig Liver Dis 2017;49:202-6. [PMID: 27876501 DOI: 10.1016/j.dld.2016.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 120 |
Stenglein J. Anesthesia for Liver Transplantation. Anesthesiology 2017. [DOI: 10.1007/978-3-319-50141-3_28] [Reference Citation Analysis]
|
| 121 |
Malespin M, Tsang R. What Do Abnormal Liver Tests Mean? Liver Disorders 2017. [DOI: 10.1007/978-3-319-30103-7_1] [Reference Citation Analysis]
|
| 122 |
Paternostro R, Reiberger T, Mandorfer M, Schwarzer R, Schwabl P, Bota S, Ferlitsch M, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. J Gastroenterol Hepatol 2017;32:184-90. [PMID: 27164413 DOI: 10.1111/jgh.13439] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 123 |
Yeboah MM. Hepatorenal Syndrome. Liver Disorders 2017. [DOI: 10.1007/978-3-319-30103-7_32] [Reference Citation Analysis]
|
| 124 |
Segarra G, Cortina B, Mauricio MD, Novella S, Lluch P, Navarrete-Navarro J, Noguera I, Medina P. Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis. World J Gastroenterol 2016; 22(48): 10545-10556 [PMID: 28082806 DOI: 10.3748/wjg.v22.i48.10545] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 125 |
Annamalai A, Harada MY, Chen M, Tran T, Ko A, Ley EJ, Nuno M, Klein A, Nissen N, Noureddin M. Predictors of Mortality in the Critically Ill Cirrhotic Patient: Is the Model for End-Stage Liver Disease Enough? J Am Coll Surg 2017;224:276-82. [PMID: 27887981 DOI: 10.1016/j.jamcollsurg.2016.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 126 |
Bucsics T, Schwabl P, Mandorfer M, Bota S, Sieghart W, Ferlitsch A, Trauner M, Reiberger T, Peck-Radosavljevic M. The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. Liver Int 2016;36:1649-56. [PMID: 27169985 DOI: 10.1111/liv.13160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 127 |
Arab JP, Claro JC, Arancibia JP, Contreras J, Gómez F, Muñoz C, Nazal L, Roessler E, Wolff R, Arrese M, Benítez C. Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. World J Hepatol 2016; 8(25): 1075-1086 [PMID: 27660674 DOI: 10.4254/wjh.v8.i25.1075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 128 |
Enescu A, Petrescu F, Mitruţ P, Petrescu IO, Pădureanu V, Enescu AŞ. Hepatorenal Syndrome: Diagnosis and Treatment - newsreel. Rom J Intern Med 2016;54:143-50. [PMID: 27658161 DOI: 10.1515/rjim-2016-0024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 129 |
Kane W. It is reasonable to treat patients with type 1 hepatorenal syndrome with midodrine and octreotide. Clin Res Pract 2016;2. [DOI: 10.22237/crp/1469036125] [Reference Citation Analysis]
|
| 130 |
Shah N, Silva RG, Kowalski A, Desai C, Lerma E. Hepatorenal syndrome. Dis Mon. 2016;62:364-375. [PMID: 27372112 DOI: 10.1016/j.disamonth.2016.05.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 131 |
Trivedi PS, Rochon PJ, Durham JD, Ryu RK. National Trends and Outcomes of Transjugular Intrahepatic Portosystemic Shunt Creation Using the Nationwide Inpatient Sample. Journal of Vascular and Interventional Radiology 2016;27:838-45. [DOI: 10.1016/j.jvir.2015.12.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 132 |
Carl DE, Ghosh SS, Gehr TW, Abbate A, Toldo S, Sanyal AJ. A model of acute kidney injury in mice with cirrhosis and infection. Liver Int 2016;36:865-73. [PMID: 26583566 DOI: 10.1111/liv.13023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 133 |
Maiwall R, Kumar S, Sharma MK, Wani Z, Ozukum M, Sarin SK. Prevalence and prognostic significance of hyperkalemia in hospitalized patients with cirrhosis. J Gastroenterol Hepatol 2016;31:988-94. [PMID: 26598065 DOI: 10.1111/jgh.13243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 134 |
Tapper EB, Bonder A, Cardenas A. Preventing and Treating Acute Kidney Injury Among Hospitalized Patients with Cirrhosis and Ascites: A Narrative Review. Am J Med 2016;129:461-7. [PMID: 26724589 DOI: 10.1016/j.amjmed.2015.12.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 135 |
Lizaola B, Bonder A, Tapper EB, Mendez-bocanegra A, Cardenas A. The Changing Role of Sodium Management in Cirrhosis. Curr Treat Options Gastro 2016;14:274-84. [DOI: 10.1007/s11938-016-0094-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 136 |
Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, Thadhani RI, Irani Z. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am J Kidney Dis 2016;68:381-91. [PMID: 26994685 DOI: 10.1053/j.ajkd.2016.02.041] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 137 |
Rathi S, Dhiman RK. Hepatobiliary Quiz Answers-17 (2016). J Clin Exp Hepatol 2016;6:73-6. [PMID: 27194902 DOI: 10.1016/j.jceh.2016.03.005] [Reference Citation Analysis]
|
| 138 |
Solà E, Huelin P, Ginès P. The Management of Hyponatremia in Cirrhosis: Should it Be Pharmacologic? Curr Hepatology Rep 2016;15:53-59. [DOI: 10.1007/s11901-016-0293-y] [Reference Citation Analysis]
|
| 139 |
Assem M, Elsabaawy M, Abdelrashed M, Elemam S, Khodeer S, Hamed W, Abdelaziz A, El-Azab G. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int. 2016;10:377-385. [PMID: 26660707 DOI: 10.1007/s12072-015-9688-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 140 |
Srivastava S, Shalimar, Vishnubhatla S, Prakash S, Sharma H, Thakur B, Acharya SK. Randomized Controlled Trial Comparing the Efficacy of Terlipressin and Albumin with a Combination of Concurrent Dopamine, Furosemide, and Albumin in Hepatorenal Syndrome. J Clin Exp Hepatol 2015;5:276-85. [PMID: 26900268 DOI: 10.1016/j.jceh.2015.08.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 141 |
Adachi M, Tanaka A, Aiso M, Takamori Y, Takikawa H. Benefit of cystatin C in evaluation of renal function and prediction of survival in patients with cirrhosis. Hepatol Res 2015;45:1299-306. [PMID: 25704216 DOI: 10.1111/hepr.12508] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 142 |
Piano S, Angeli P. Dopamine and Furosemide for the Treatment of Hepatorenal Syndrome: A Reappraisal or Just Smoke and Mirrors? J Clin Exp Hepatol 2015;5:273-5. [PMID: 26900267 DOI: 10.1016/j.jceh.2015.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 143 |
Garcia-tsao G. Ascites and Its Complications. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch106] [Reference Citation Analysis]
|
| 144 |
Velez JC, Kadian M, Taburyanskaya M, Bohm NM, Delay TA, Karakala N, Rockey DC, Nietert PJ, Goodwin AJ, Whelan TP. Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure. Nephron 2015;131:191-201. [PMID: 26485256 DOI: 10.1159/000441151] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 145 |
Maiwall R, Sarin SK, Moreau R. Acute kidney injury in acute on chronic liver failure. Hepatol Int 2016;10:245-57. [DOI: 10.1007/s12072-015-9652-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 146 |
Bittencourt PL, Farias AQ, Terra C. Renal failure in cirrhosis: Emerging concepts. World J Hepatol 2015; 7(21): 2336-2343 [PMID: 26413223 DOI: 10.4254/wjh.v7.i21.2336] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 147 |
Kerbert AJ, Verbeke L, Chiang FW, Laleman W, van der Reijden JJ, van Duijn W, Nevens F, Wolterbeek R, van Hoek B, Verspaget HW, Coenraad MJ. Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis. PLoS One 2015;10:e0138264. [PMID: 26378453 DOI: 10.1371/journal.pone.0138264] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 148 |
Russ KB, Stevens TM, Singal AK. Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol. 2015;3:195-204. [PMID: 26623266 DOI: 10.14218/jcth.2015.00015] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 149 |
Aggarwal HK, Jain D, Singla S, Jain P. Assessment of renal functions in patients of chronic liver disease. Ren Fail 2015;37:1457-63. [PMID: 26338024 DOI: 10.3109/0886022X.2015.1077318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 150 |
Saxena V, Lai JC. Kidney Failure and Liver Allocation: Current Practices and Potential Improvements. Adv Chronic Kidney Dis 2015;22:391-8. [PMID: 26311601 DOI: 10.1053/j.ackd.2015.05.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 151 |
Al-khafaji A, Nadim MK, Kellum JA. Hepatorenal Disorders. Chest 2015;148:550-8. [DOI: 10.1378/chest.14-1925] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 152 |
Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology 2015;62:567-74. [PMID: 25644760 DOI: 10.1002/hep.27709] [Cited by in Crossref: 211] [Cited by in F6Publishing: 180] [Article Influence: 26.4] [Reference Citation Analysis]
|
| 153 |
Romano TG, Vieira Junior JM. Do Biliary Salts Have Role on Acute Kidney Injury Development? J Clin Med Res 2015;7:667-71. [PMID: 26251679 DOI: 10.14740/jocmr2261w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 154 |
Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, Tamez H, Chung RT, Karumanchi SA, Thadhani RI. Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int J Nephrol. 2015;2015:108139. [PMID: 26266048 DOI: 10.1155/2015/108139] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 155 |
Shah NL, Banaei YP, Hojnowski KL, Cornella SL. Management options in decompensated cirrhosis. Hepat Med 2015;7:43-50. [PMID: 26203291 DOI: 10.2147/HMER.S62463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 156 |
Potosek J, Curry M, Buss M, Chittenden E. Integration of palliative care in end-stage liver disease and liver transplantation. J Palliat Med. 2014;17:1271-1277. [PMID: 25390468 DOI: 10.1089/jpm.2013.0167] [Cited by in Crossref: 74] [Cited by in F6Publishing: 81] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 157 |
Hassan EA, Abdel Rehim AS. Creatinine modified Child-Turcotte-Pugh and integrated model of end-stage liver disease scores as predictors of spontaneous bacterial peritonitis-related in-hospital mortality: Applicable or not. J Gastroenterol Hepatol 2015;30:1205-10. [PMID: 25678363 DOI: 10.1111/jgh.12918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 158 |
Tong W, Hurley S, Hayashi PH. Reconsidering hepatorenal syndrome: Throw in the towel? Not so fast! Postgraduate Medicine 2015;116:15-24. [DOI: 10.3810/pgm.2004.12.1625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 159 |
Zhang Z, Maddukuri G, Jaipaul N, Cai CX. Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. J Crit Care. 2015;30:969-974. [PMID: 26051980 DOI: 10.1016/j.jcrc.2015.05.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 160 |
Didsbury MS, Mackie FE, Kennedy SE. A systematic review of acute kidney injury in pediatric allogeneic hematopoietic stem cell recipients. Pediatr Transplant 2015;19:460-70. [PMID: 25963934 DOI: 10.1111/petr.12483] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 161 |
Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Ther Adv Chronic Dis 2015;6:124-37. [PMID: 25954497 DOI: 10.1177/2040622315580069] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 162 |
Dundar HZ, Yılmazlar T. Management of hepatorenal syndrome. World J Nephrol 2015; 4(2): 277-286 [PMID: 25949942 DOI: 10.5527/wjn.v4.i2.277] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 163 |
Cai CX, Maddukuri G, Jaipaul N, Zhang Z. A Treat-to-Target Concept to Guide the Medical Management of Hepatorenal Syndrome. Dig Dis Sci 2015;60:1474-81. [PMID: 25532500 DOI: 10.1007/s10620-014-3483-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 164 |
Low G, Owen NE, Joubert I, Patterson AJ, Graves MJ, Alexander GJ, Lomas DJ. Magnetic resonance elastography in the detection of hepatorenal syndrome in patients with cirrhosis and ascites. Eur Radiol. 2015;25:2851-2858. [PMID: 25903705 DOI: 10.1007/s00330-015-3723-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 165 |
Heidemann J, Bartels C, Berssenbrügge C, Schmidt H, Meister T. Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract. 2015;2015:457613. [PMID: 25983746 DOI: 10.1155/2015/457613] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 166 |
Janicko M, Veseliny E, Senajova G, Jarcuska P. Predictors of hepatorenal syndrome in alcoholic liver cirrhosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:661-5. [PMID: 25820623 DOI: 10.5507/bp.2015.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 167 |
Farag E, Maheshwari K, Morgan J, Sakr Esa WA, Doyle DJ. An update of the role of renin angiotensin in cardiovascular homeostasis. Anesth Analg 2015;120:275-92. [PMID: 25602448 DOI: 10.1213/ANE.0000000000000528] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 168 |
Mehta G, Mookerjee RP, Sharma V, Jalan R. Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure. Liver Int 2015;35:724-34. [PMID: 24703488 DOI: 10.1111/liv.12559] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 169 |
Deepak A, Mrudul VD, Madhuri C, Rajiv B, Praveen K, Mayank J, Nikhil P, Praful K, Nimish S, Sandeep K, Sonali G, Apurva S, Soham D. Care of patients with liver cirrhosis: How are we doing? J Public Health Epidemiol 2015;7:51-58. [DOI: 10.5897/jphe2014.0695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 170 |
Israelsen M, Krag A, Gluud LL. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database of Systematic Reviews 2015. [DOI: 10.1002/14651858.cd011532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 171 |
Egerod Israelsen M, Gluud LL, Krag A. Acute kidney injury and hepatorenal syndrome in cirrhosis. J Gastroenterol Hepatol 2015;30:236-43. [PMID: 25160511 DOI: 10.1111/jgh.12709] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 172 |
Bozanich NK, Kwo PY. Renal insufficiency in the patient with chronic liver disease. Clin Liver Dis 2015;19:45-56. [PMID: 25454296 DOI: 10.1016/j.cld.2014.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 173 |
Cárdenas A, Graupera I, Ginès P. Ascites. Cirrhosis: A practical guide to management 2015. [DOI: 10.1002/9781118412640.ch14] [Reference Citation Analysis]
|
| 174 |
Adebayo D, Morabito V, Jalan R. Acute-on-chronic liver failure. Cirrhosis: A practical guide to management 2015. [DOI: 10.1002/9781118412640.ch09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 175 |
Piano S, Morando F, Angeli P. Hyponatremia and other electrolyte/ion disorders. Cirrhosis: A practical guide to management 2015. [DOI: 10.1002/9781118412640.ch18] [Reference Citation Analysis]
|
| 176 |
Low G, Alexander GJ, Lomas DJ. Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract 2015;2015:207012. [PMID: 25649410 DOI: 10.1155/2015/207012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 177 |
Park SH, Park C, Yoo J, Choi S, Choi J, Shin H, Lee D, Lee S, Kim J, Choi SE, Kwon Y, Shin W. Emergence of Community-Associated Methicillin-Resistant Staphylococcus aureus Strains as a Cause of Healthcare-Associated Bloodstream Infections in Korea. Infect Control Hosp Epidemiol 2009;30:146-55. [DOI: 10.1086/593953] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 178 |
Pham PT, Parke C, Allamezadeh R, Pham PT, Danovitch GM. Renal Failure in Adults. Transplantation of the Liver 2015. [DOI: 10.1016/b978-1-4557-0268-8.00074-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 179 |
Fayad L, Narciso-Schiavon JL, Lazzarotto C, Ronsoni MF, Wildner LM, Bazzo ML, Schiavon Lde L, Dantas-Corrêa EB. The performance of prognostic models as predictors of mortality in patients with acute decompensation of cirrhosis. Ann Hepatol 2015;14:83-92. [PMID: 25536645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 180 |
Mai ML, Wadei HM. Pretransplantation Evaluation. Transplantation of the Liver 2015. [DOI: 10.1016/b978-1-4557-0268-8.00032-4] [Reference Citation Analysis]
|
| 181 |
Jahn M, Bienholz A, Kribben A. Akutes Nierenversagen: Pathophysiologie, Prävention, Therapie und Sonderformen. DGIM Innere Medizin 2015. [DOI: 10.1007/978-3-642-54676-1_75-1] [Reference Citation Analysis]
|
| 182 |
Marik PE. Acute and Chronic Liver Disease. Evidence-Based Critical Care 2015. [DOI: 10.1007/978-3-319-11020-2_34] [Reference Citation Analysis]
|
| 183 |
Bernardi M, Ricci CS, Santi L. Hyponatremia in Patients with Cirrhosis of the Liver. J Clin Med. 2014;4:85-101. [PMID: 26237020 DOI: 10.3390/jcm4010085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 184 |
Cimen S, Guler S, Ayloo S, Molinari M. Implications of Hyponatremia in Liver Transplantation. J Clin Med 2014;4:66-74. [PMID: 26237018 DOI: 10.3390/jcm4010066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 185 |
Ennaifer R, Romdhane H, Hefaiedh R, Nejma HB, Hadj NB. Insuffisance rénale aigüe chez le patient cirrhotique : particularités diagnostiques et thérapeutiques. J Afr Hepato Gastroenterol 2014;8:189-194. [DOI: 10.1007/s12157-014-0552-x] [Reference Citation Analysis]
|
| 186 |
Facciorusso A, Amoruso A, Neve V, Antonino M, Prete VD, Barone M. Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. World J Hepatol 2014; 6(11): 793-799 [PMID: 25429317 DOI: 10.4254/wjh.v6.i11.793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 187 |
Chan AC, Fan ST. Criteria for liver transplantation in ACLF and outcome. Hepatol Int. 2015;9:355-359. [PMID: 25788183 DOI: 10.1007/s12072-014-9585-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 188 |
Siddiqui MS, Stravitz RT. Intensive care unit management of patients with liver failure. Clin Liver Dis 2014;18:957-78. [PMID: 25438294 DOI: 10.1016/j.cld.2014.07.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 189 |
DellaVolpe JD, Garavaglia JM, Huang DT. Management of Complications of End-Stage Liver Disease in the Intensive Care Unit. J Intensive Care Med 2016;31:94-103. [PMID: 25223828 DOI: 10.1177/0885066614551144] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 190 |
Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One 2014;9:e107466. [PMID: 25203311 DOI: 10.1371/journal.pone.0107466] [Cited by in Crossref: 94] [Cited by in F6Publishing: 98] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 191 |
Torruellas C, French SW, Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol 2014; 20(33): 11684-11699 [PMID: 25206273 DOI: 10.3748/wjg.v20.i33.11684] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 93] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 192 |
Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol 2014;61:396-407. [PMID: 24751830 DOI: 10.1016/j.jhep.2014.04.012] [Cited by in Crossref: 281] [Cited by in F6Publishing: 285] [Article Influence: 31.2] [Reference Citation Analysis]
|
| 193 |
Biolato M, Miele L, Vero V, Racco S, Stasi CD, Iezzi R, Zanché A, Pompili M, Rapaccini GL, Torre GL, Gasbarrini A, Grieco A. Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: Serum sodium predicts survival. World J Gastroenterol 2014; 20(25): 8158-8165 [PMID: 25009388 DOI: 10.3748/wjg.v20.i25.8158] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 194 |
Leise MD, Yun BC, Larson JJ, Benson JT, Yang JD, Therneau TM, Rosen CB, Heimbach JK, Biggins SW, Kim WR. Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. Liver Transpl 2014;20:687-97. [PMID: 24616214 DOI: 10.1002/lt.23860] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 195 |
Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Junuzovic D, Bijedic N, Sofic A, Bjelogrlic I, Mehmedovic A. Estimated Glomerular Filtration Rate (eGFR) Values as Predictor of Renal Insufficiency in Advanced Stages of Liver Diseases with Different Etiology. Med Arch 2014;68:159-62. [PMID: 25568524 DOI: 10.5455/medarh.2014.68.159-162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 196 |
Ripoll C, Zipprich A, Garcia-tsao G. Prognostic Factors in Compensated and Decompensated Cirrhosis. Curr Hepatology Rep 2014;13:171-9. [DOI: 10.1007/s11901-014-0234-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 197 |
Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: Evidence based treatment. World J Gastroenterol 2014; 20(18): 5442-5460 [PMID: 24833875 DOI: 10.3748/wjg.v20.i18.5442] [Cited by in CrossRef: 118] [Cited by in F6Publishing: 128] [Article Influence: 13.1] [Reference Citation Analysis]
|
| 198 |
Pugliese R, Fonseca EA, Porta G, Danesi V, Guimaraes T, Porta A, Miura IK, Borges C, Candido H, Benavides M, Feier FH, Godoy A, Cardoso RA, Kondo M, Chapchap P, Neto JS. Ascites and serum sodium are markers of increased waiting list mortality in children with chronic liver failure. Hepatology 2014;59:1964-71. [PMID: 24122953 DOI: 10.1002/hep.26776] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 199 |
Francoz C, Nadim MK, Baron A, Prié D, Antoine C, Belghiti J, Valla D, Moreau R, Durand F. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. Hepatology 2014;59:1514-21. [PMID: 24037821 DOI: 10.1002/hep.26704] [Cited by in Crossref: 96] [Cited by in F6Publishing: 71] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 200 |
Leithead JA, Hayes PC, Ferguson JW. Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction. Aliment Pharmacol Ther 2014;39:699-711. [PMID: 24528130 DOI: 10.1111/apt.12653] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 201 |
Abu Zeinah GF, Al-Kindi SG, Hassan AA, Allam A. Hyponatraemia in cancer: association with type of cancer and mortality. Eur J Cancer Care (Engl) 2015;24:224-31. [PMID: 24661476 DOI: 10.1111/ecc.12187] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 202 |
Maddukuri G, Cai CX, Munigala S, Mohammadi F, Zhang Z. Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. Dig Dis Sci 2014;59:471-81. [PMID: 24146317 DOI: 10.1007/s10620-013-2899-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 203 |
Bonder A, Botero ML, Cardenas A. Current Therapies for Hepatorenal Syndrome. Curr Hepatology Rep 2014;13:74-80. [DOI: 10.1007/s11901-014-0217-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 204 |
Zhang X, Huang S, Gao M, Liu J, Jia X, Han Q, Zheng S, Miao Y, Li S, Weng H, Xia X, Du S, Wu W, Gustafsson JÅ, Guan Y. Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice. Proc Natl Acad Sci U S A 2014;111:2277-82. [PMID: 24464484 DOI: 10.1073/pnas.1323977111] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 205 |
Seo JH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Ahn SH. Predictors of refractory ascites development in patients with hepatitis B virus-related cirrhosis hospitalized to control ascitic decompensation. Yonsei Med J 2013;54:145-53. [PMID: 23225811 DOI: 10.3349/ymj.2013.54.1.145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 206 |
Fabrizi F, Martin P, Messa P. Recent advances in the management of hepato-renal syndrome (HRS). Acta Clin Belg 2007;62 Suppl 2:393-6. [PMID: 18284007 DOI: 10.1179/acb.2007.088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 207 |
Kiser TH. Hepatorenal Syndrome. Int J Clin Med 2014;5:102-10. [PMID: 32284909 DOI: 10.4236/ijcm.2014.53018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 208 |
Miyoshi T, Kitamura K. 8. Distant Organ Dysfunction Associated with AKI. J Jpn Soc Intern Med 2014;103:1123-1129. [DOI: 10.2169/naika.103.1123] [Reference Citation Analysis]
|
| 209 |
Carey EJ, Rakela J, Vargas HE. Monitoring and Care. Transplantation of the Liver 2014. [DOI: 10.1016/b978-1-4557-0268-8.00036-1] [Reference Citation Analysis]
|
| 210 |
O’riordan A. Hepatorenal Syndrome. Practical Nephrology 2014. [DOI: 10.1007/978-1-4471-5547-8_8] [Reference Citation Analysis]
|
| 211 |
Pillebout E. Hepatorenal syndrome. Nephrol Ther. 2014;10:61-68. [PMID: 24388293 DOI: 10.1016/j.nephro.2013.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 212 |
Licata A, Maida M, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, Almasio PL. Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World J Hepatol 2013; 5(12): 685-691 [PMID: 24432185 DOI: 10.4254/wjh.v5.i12.685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 213 |
Chan MM, Chan MM, Mengshol JA, Fish DN, Chan ED. Octreotide. Chest 2013;144:1937-45. [DOI: 10.1378/chest.13-0382] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 214 |
Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126:S1-S42. [PMID: 24074529 DOI: 10.1016/j.amjmed.2013.07.006] [Cited by in Crossref: 582] [Cited by in F6Publishing: 633] [Article Influence: 58.2] [Reference Citation Analysis]
|
| 215 |
Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol 2014;65:723-30. [PMID: 24184025 DOI: 10.1016/j.eururo.2013.10.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 216 |
Verna EC, Wagener G. Renal interactions in liver dysfunction and failure. Curr Opin Crit Care 2013;19:133-41. [PMID: 23422161 DOI: 10.1097/MCC.0b013e32835ebb3a] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 217 |
Barone C, Koeberle D, Metselaar H, Parisi G, Sansonno D, Spinzi G. Multidisciplinary approach for HCC patients: hepatology for the oncologists. Ann Oncol. 2013;24 Suppl 2:ii15-ii23. [PMID: 23715939 DOI: 10.1093/annonc/mdt053] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 218 |
Mohindra S, Kumar K. Hepatorenal syndrome. Clinical Queries: Nephrology 2013;2:205-211. [DOI: 10.1016/j.cqn.2013.11.002] [Reference Citation Analysis]
|
| 219 |
Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int 2013;33:1187-93. [PMID: 23601499 DOI: 10.1111/liv.12179] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 220 |
Huschak G, Kaisers U, Laudi S. Hepatorenales Syndrom. Anaesthesist 2013;62:571-82. [DOI: 10.1007/s00101-013-2197-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 221 |
Götzberger M, Singer J, Kaiser C, Gülberg V. Intrarenal resistance index as a prognostic parameter in patients with liver cirrhosis compared with other hepatic scoring systems. Digestion 2012;86:349-54. [PMID: 23207318 DOI: 10.1159/000343459] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 222 |
Xing T, Zhong L, Chen D, Peng Z. Experience of Combined Liver-Kidney Transplantation for Acute-on-Chronic Liver Failure Patients With Renal Dysfunction. Transplantation Proceedings 2013;45:2307-13. [DOI: 10.1016/j.transproceed.2013.02.127] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 223 |
Kim HJ, Lee HW. Important predictor of mortality in patients with end-stage liver disease. Clin Mol Hepatol. 2013;19:105-115. [PMID: 23837134 DOI: 10.3350/cmh.2013.19.2.105] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 224 |
Allegretti AS, Steele DJ, David-Kasdan JA, Bajwa E, Niles JL, Bhan I. Continuous renal replacement therapy outcomes in acute kidney injury and end-stage renal disease: a cohort study. Crit Care 2013;17:R109. [PMID: 23782899 DOI: 10.1186/cc12780] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 225 |
Bertot LC, Gomez EV, Almeida LA, Soler EA, Perez LB. Model for End-Stage Liver Disease and liver cirrhosis-related complications. Hepatol Int 2013;7:347-55. [PMID: 26201769 DOI: 10.1007/s12072-012-9403-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 226 |
Gülberg V, Gerbes A. Komplikationen der Leberzirrhose. Gastroenterologe 2013;8:241-249. [DOI: 10.1007/s11377-013-0751-9] [Reference Citation Analysis]
|
| 227 |
van Slambrouck CM, Salem F, Meehan SM, Chang A. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int. 2013;84:192-197. [PMID: 23486516 DOI: 10.1038/ki.2013.78] [Cited by in Crossref: 135] [Cited by in F6Publishing: 141] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 228 |
Shah N, Mohamed FE, Jover-Cobos M, Macnaughtan J, Davies N, Moreau R, Paradis V, Moore K, Mookerjee R, Jalan R. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int 2013;33:398-409. [PMID: 23402610 DOI: 10.1111/liv.12047] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 229 |
Lau T, Ahmad J. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med. 2013;5:1-10. [PMID: 24696621 DOI: 10.2147/hmer.s9049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 230 |
Solà E, Cárdenas A, Ginès P. Hyponatremia in Cirrhosis: Evaluation and Treatment. Hyponatremia 2013. [DOI: 10.1007/978-1-4614-6645-1_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 231 |
Judd EK, Mehta S, Tolwani AJ. Specific Etiologies. Clinical Decisions in Nephrology, Hypertension and Kidney Transplantation 2013. [DOI: 10.1007/978-1-4614-4454-1_21] [Reference Citation Analysis]
|
| 232 |
Fukazawa K, Lee HT. Updates on Hepato-Renal Syndrome. J Anesth Clin Res. 2013;4:352. [PMID: 24459604 DOI: 10.4172/2155-6148.1000352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 233 |
Ginès P, Cárdenas A, Schrier RW. Renal Failure in Cirrhosis. Seldin and Giebisch's The Kidney. Elsevier; 2013. pp. 2633-44. [DOI: 10.1016/b978-0-12-381462-3.00079-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 234 |
Jafri S, Gordon SC. Care of the Cirrhotic Patient. Infectious Disease Clinics of North America 2012;26:979-94. [DOI: 10.1016/j.idc.2012.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 235 |
Schrier RW, Sharma S, Shchekochikhin D. Hyponatraemia: more than just a marker of disease severity? Nat Rev Nephrol. 2013;9:37-50. [PMID: 23165296 DOI: 10.1038/nrneph.2012.246] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 236 |
Weber ML, Ibrahim HN, Lake JR. Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl 2012;18:1290-301. [PMID: 22847917 DOI: 10.1002/lt.23522] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 237 |
Lata J. Hepatorenal syndrome. World J Gastroenterol 2012; 18(36): 4978-4984 [PMID: 23049205 DOI: 10.3748/wjg.v18.i36.4978] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 238 |
Al-Busafi SA, McNabb-Baltar J, Farag A, Hilzenrat N. Clinical manifestations of portal hypertension. Int J Hepatol. 2012;2012:203794. [PMID: 23024865 DOI: 10.1155/2012/203794] [Cited by in Crossref: 32] [Cited by in F6Publishing: 67] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 239 |
Davenport A. AKI in a patient with cirrhosis and ascites. Clin J Am Soc Nephrol. 2012;7:2041-2048. [PMID: 22977213 DOI: 10.2215/cjn.03390412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 240 |
Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2012;9:CD005162. [PMID: 22972083 DOI: 10.1002/14651858.cd005162.pub3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 66] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 241 |
Makhlouf NA, Morsy KH. Renal failure after upper-gastrointestinal bleeding among cirrhotic patients in Upper Egypt. Arab J Gastroenterol 2012;13:139-44. [PMID: 23122456 DOI: 10.1016/j.ajg.2012.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 242 |
Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, Sise ME, Oliver JA, Radhakrishnan J, Barasch JM, Nickolas TL. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012;57:2362-70. [PMID: 22562534 DOI: 10.1007/s10620-012-2180-x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 104] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 243 |
Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol 2012; 18(24): 3035-3049 [PMID: 22791939 DOI: 10.3748/wjg.v18.i24.3035] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 244 |
Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci (Lond). 2012;123:225-239. [PMID: 22548407 DOI: 10.1042/cs20120030] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 245 |
Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, Sharma AK, Choudhary NS, Chawla Y, Nain CK. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012;56:1293-8. [PMID: 22322237 DOI: 10.1016/j.jhep.2012.01.012] [Cited by in Crossref: 168] [Cited by in F6Publishing: 173] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 246 |
Tan H, Schiano TD. Effects of Liver Disease on Drug Metabolism in Humans. Encyclopedia of Drug Metabolism and Interactions. Hoboken: John Wiley & Sons, Inc.; 2011. [DOI: 10.1002/9780470921920.edm125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 247 |
Gordon FD. Ascites. Clin Liver Dis 2012;16:285-99. [PMID: 22541699 DOI: 10.1016/j.cld.2012.03.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 248 |
Coilly A, Samuel D. Selection and Evaluation of the Recipient (Including Retransplantation). Medical Care of the Liver Transplant Patient 2012. [DOI: 10.1002/9781444398441.ch1] [Reference Citation Analysis]
|
| 249 |
Fagundes C, Ginès P. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. Am J Kidney Dis. 2012;59:874-885. [PMID: 22480795 DOI: 10.1053/j.ajkd.2011.12.032] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 250 |
Fede G, D'Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, Morabito A, Burroughs AK. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012;56:810-8. [PMID: 22173162 DOI: 10.1016/j.jhep.2011.10.016] [Cited by in Crossref: 185] [Cited by in F6Publishing: 186] [Article Influence: 16.8] [Reference Citation Analysis]
|
| 251 |
Schrier RW. Use of diuretics in heart failure and cirrhosis. Semin Nephrol 2011;31:503-12. [PMID: 22099507 DOI: 10.1016/j.semnephrol.2011.09.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 252 |
Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, Uemura M, Fukui H, Sumino Y, Matsuzaki Y, Masaki N, Kokubu S, Okita K. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol 2012;47:313-20. [PMID: 22038555 DOI: 10.1007/s00535-011-0485-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 253 |
Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, Bellomo R, Genyk YS; ADQI Workgroup. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012;16:R23. [PMID: 22322077 DOI: 10.1186/cc11188] [Cited by in Crossref: 112] [Cited by in F6Publishing: 121] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 254 |
Olivera-Martinez M, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Hepatorenal syndrome: are we missing some prognostic factors? Dig Dis Sci 2012;57:210-4. [PMID: 21850494 DOI: 10.1007/s10620-011-1861-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 255 |
Garcia-tsao G. Ascites. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 283-95. [DOI: 10.1016/b978-1-4377-0881-3.00018-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 256 |
Diaz G. Combined Solid Organ Transplantation Involving the Liver. Liver Anesthesiology and Critical Care Medicine 2012. [DOI: 10.1007/978-1-4614-5167-9_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 257 |
Levesque E, Hoti E, Azoulay D, Ichaï P, Habouchi H, Castaing D, Samuel D, Saliba F. Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol 2012;56:95-102. [PMID: 21835136 DOI: 10.1016/j.jhep.2011.06.024] [Cited by in Crossref: 129] [Cited by in F6Publishing: 125] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 258 |
Susla GM, Lertora JJ. Effect of Liver Disease on Pharmacokinetics. Principles of Clinical Pharmacology 2012. [DOI: 10.1016/b978-0-12-385471-1.00007-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 259 |
Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients. J Hepatol 2012;56 Suppl 1:S13-24. [PMID: 22300462 DOI: 10.1016/S0168-8278(12)60003-8] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 260 |
Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med 2012;33:209-90. [PMID: 22230555 DOI: 10.1016/j.mam.2011.12.002] [Cited by in Crossref: 983] [Cited by in F6Publishing: 1030] [Article Influence: 81.9] [Reference Citation Analysis]
|
| 261 |
Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, Wilmer A, Verslype C, Nevens F. Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol. 2011;5:523-537; quiz 537. [PMID: 21780899 DOI: 10.1586/egh.11.47] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 262 |
Patterson JH. Hyponatremia's Impact on Patients and Health Systems. Hosp Pharm 2011;46:3-10. [DOI: 10.1310/hpj4612-s3] [Reference Citation Analysis]
|
| 263 |
Tahir F, Riaz H, Rehman A, Munir MB. Potential role of TNF alpha blockers in delaying the progression of hepato-renal syndrome. Med Hypotheses. 2012;78:225-226. [PMID: 22094211 DOI: 10.1016/j.mehy.2011.10.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 264 |
Kim DJ, Kang HS, Choi HS, Cho HJ, Kim ES, Keum B, An H, Kim JH, Seo YS, Kim YS. Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels. Korean J Hepatol. 2011;17:130-138. [PMID: 21757984 DOI: 10.3350/kjhep.2011.17.2.130] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 265 |
Gundling F, Schmidt T, Schepp W. Common complications of cirrhosis: do we follow too often the 'Casablanca strategy'? Liver Int 2011;31:1598-600. [PMID: 21745306 DOI: 10.1111/j.1478-3231.2011.02565.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 266 |
Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P; Terlipressin Study Group. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 2011;17:1328-32. [PMID: 21837734 DOI: 10.1002/lt.22395] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 267 |
Tan HH, Martin P. Care of the liver transplant candidate. Clin Liver Dis 2011;15:779-806. [PMID: 22032529 DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 268 |
Madan K, Mehta A. Management of renal failure and ascites in patients with cirrhosis. Int J Hepatol 2011;2011:790232. [PMID: 21994871 DOI: 10.4061/2011/790232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 269 |
Memon I, Klein CL. Impact of hepatorenal syndrome and liver transplantation. Curr Opin Organ Transplant 2011;16:301-5. [PMID: 21505341 DOI: 10.1097/MOT.0b013e328346576c] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 270 |
Srivastava B, Alexander GJ. Renal failure in chronic liver disease and the hepatorenal syndrome. British Journal of Hospital Medicine 2011;72:497-503. [DOI: 10.12968/hmed.2011.72.9.497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 271 |
Patel PA, Lowe E, Baig W, Sandoe J. Hepatorenal syndrome precipitated by infective endocarditis. British Journal of Hospital Medicine 2011;72:532-3. [DOI: 10.12968/hmed.2011.72.9.532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 272 |
Wadei HM, Gonwa TA. Hepatorenal syndrome in the intensive care unit. J Intensive Care Med. 2013;28:79-92. [PMID: 21859679 DOI: 10.1177/0885066611408692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 273 |
Dancygier H. Aszites. DoctorConsult - The Journal Wissen für Klinik und Praxis 2011;2:e87-e96. [DOI: 10.1016/j.dcjwkp.2011.07.006] [Reference Citation Analysis]
|
| 274 |
Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2011;55:315-21. [PMID: 21167235 DOI: 10.1016/j.jhep.2010.11.020] [Cited by in Crossref: 161] [Cited by in F6Publishing: 164] [Article Influence: 13.4] [Reference Citation Analysis]
|
| 275 |
Sarin SK, Sharma P. Terlipressin: an asset for hepatologists! Hepatology 2011;54:724-8. [PMID: 21735463 DOI: 10.1002/hep.24519] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 276 |
Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation. 2011;91:1141-1147. [PMID: 21544034 DOI: 10.1097/tp.0b013e31821690bf] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 277 |
Prakash J, Mahapatra AK, Ghosh B, Arora P, Jain AK. Clinical spectrum of renal disorders in patients with cirrhosis of liver. Ren Fail 2011;33:40-6. [PMID: 21219204 DOI: 10.3109/0886022X.2010.541582] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 278 |
Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol 2011;54:1297-306. [PMID: 21145851 DOI: 10.1016/j.jhep.2010.11.008] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 279 |
Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011;140:1952-60. [PMID: 21334338 DOI: 10.1053/j.gastro.2011.02.017] [Cited by in Crossref: 103] [Cited by in F6Publishing: 108] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 280 |
Arora R, Kathuria S, Jalandhara N. Acute renal dysfunction in patients with alcoholic hepatitis. World J Hepatol 2011; 3(5): 121-124 [PMID: 21731905 DOI: 10.4254/wjh.v3.i5.121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 281 |
Garcia-tsao G. Ascites. Sherlock's Diseases of the Liver and Biliary System 2011. [DOI: 10.1002/9781444341294.ch10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 282 |
Schrier RW. The Science Behind Hyponatremia and Its Clinical Manifestations. Pharmacotherapy 2011;31:9S-17S. [DOI: 10.1592/phco.31.5.9s] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 283 |
Cerdá J, Tolwani A, Gibney N, Tiranathanagul K. Renal Replacement Therapy in Special Settings: Extracorporeal Support Devices in Liver Failure: EXTRACORPOREAL DEVICES IN LIVER FAILURE. Seminars in Dialysis 2011;24:197-202. [DOI: 10.1111/j.1525-139x.2011.00827.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 284 |
Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig Dis Sci 2011;56:977-87. [PMID: 20844956 DOI: 10.1007/s10620-010-1390-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 285 |
Park I, Moon E, Hwang JA, Yu S, Kim BW, Wang HJ, Shin GT, Kim H. Does hepatorenal syndrome affect the result of liver transplantation? Clinical observations. Transplant Proc. 2010;42:2563-2566. [PMID: 20832544 DOI: 10.1016/j.transproceed.2010.04.049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 286 |
Somsouk M, Kornfield R, Vittinghoff E, Inadomi JM, Biggins SW. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl 2011;17:129-36. [PMID: 21280185 DOI: 10.1002/lt.22218] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 287 |
Leise MD, Kim WR, Kamath PS. Issues in Transplantation of Patients with Chronic Liver Failure. Chronic Liver Failure 2011. [DOI: 10.1007/978-1-60761-866-9_26] [Reference Citation Analysis]
|
| 288 |
Mazhar SM, Hanna R, Peterson MR, Sirlin CB. Cirrhosis. Abdominal Imaging 2011. [DOI: 10.1016/b978-1-4160-5449-8.00066-4] [Reference Citation Analysis]
|
| 289 |
Coilly A, Samuel D. Cirrhose et transplantation: quand faut-il y penser? Post’U FMC-HGE 2011. [DOI: 10.1007/978-2-8178-0237-4_34] [Reference Citation Analysis]
|
| 290 |
Slack A, Wendon J. Chronic Liver Disease in the Intensive Care. Chronic Liver Failure 2011. [DOI: 10.1007/978-1-60761-866-9_27] [Reference Citation Analysis]
|
| 291 |
Dhillon A. Hepatorenal Syndrome. Textbook of Critical Care 2011. [DOI: 10.1016/b978-1-4377-1367-1.00099-9] [Reference Citation Analysis]
|
| 292 |
Fleming JN, Abou Abbass A. Hepatorenal syndrome: a comprehensive overview for the critical care nurse. Crit Care Nurs Clin North Am 2010;22:351-68. [PMID: 20691386 DOI: 10.1016/j.ccell.2010.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 293 |
Kalambokis GN, Pappas K, Baltayiannis G, Katsanou A, Tsianos EV. Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia. Scand J Gastroenterol 2010;45:1509-15. [PMID: 20695722 DOI: 10.3109/00365521.2010.510576] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 294 |
Kim YS. [Ascites, hepatorenal syndrome and spontaneous bacterial peritonitis in patients with portal hypertension]. Korean J Gastroenterol 2010;56:168-85. [PMID: 20847607 DOI: 10.4166/kjg.2010.56.3.168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 295 |
Moini M, Hoseini-asl MK, Taghavi SA, Sagheb MM, Nikeghbalian S, Salahi H, Bahador A, Motazedian M, Jafari P, Malek-hosseini SA. Hyponatremia a valuable predictor of early mortality in patients with cirrhosis listed for liver transplantation: Hyponatremia and liver list mortality. Clinical Transplantation 2011;25:638-45. [DOI: 10.1111/j.1399-0012.2010.01350.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 296 |
Canbay A, Witzke O, Gerken G. Hepatorenales Syndrom. Intensivmed 2010;47:565-570. [DOI: 10.1007/s00390-010-0192-3] [Reference Citation Analysis]
|
| 297 |
Bagshaw SM, Bellomo R, Devarajan P, Johnson C, Karvellas CJ, Kutsiogiannis DJ, Mehta R, Pannu N, Romanovsky A, Sheinfeld G, Taylor S, Zappitelli M, Gibney RTN. Review article: Acute kidney injury in critical illness. Can J Anesth/J Can Anesth 2010;57:985-98. [DOI: 10.1007/s12630-010-9375-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 298 |
Francoz C, Prié D, Abdelrazek W, Moreau R, Mandot A, Belghiti J, Valla D, Durand F. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transpl 2010;16:1169-77. [PMID: 20879015 DOI: 10.1002/lt.22128] [Cited by in Crossref: 137] [Cited by in F6Publishing: 94] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 299 |
Barahona-Garrido J, Hernández-Calleros J, Téllez-Avila FI, Chávez-Tapia NC, Remes-Troche JM, Torre A. Bacterial meningitis in cirrhotic patients: case series and description of the prognostic role of acute renal failure. J Clin Gastroenterol 2010;44:e218-23. [PMID: 20453662 DOI: 10.1097/MCG.0b013e3181d88d53] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 300 |
Rozov-ung I, Panesar M. The use of terlipressin in hepatorenal syndrome. Dial Transplant 2010;39:420-426. [DOI: 10.1002/dat.20492] [Reference Citation Analysis]
|
| 301 |
Ginès P, Cárdenas A, Arroyo V, Rodés J. Ascites, Hepatorenal Syndrome and Spontaneous Bacterial Peritonitis. Evidence‐Based Gastroenterology and Hepatology 2010. [DOI: 10.1002/9781444314403.ch38] [Reference Citation Analysis]
|
| 302 |
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417. [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004] [Cited by in Crossref: 1110] [Cited by in F6Publishing: 1165] [Article Influence: 85.4] [Reference Citation Analysis]
|
| 303 |
Guevara M, Baccaro ME, Ríos J, Martín-Llahí M, Uriz J, Ruiz del Arbol L, Planas R, Monescillo A, Guarner C, Crespo J, Bañares R, Arroyo V, Ginès P. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int 2010;30:1137-42. [PMID: 20602681 DOI: 10.1111/j.1478-3231.2010.02293.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 304 |
Kumar S, Balki M, Williamson C, Castillo E, Money DM. Disorders of the Liver, Biliary System and Exocrine Pancreas in Pregnancy. de Swiet's Medical Disorders in Obstetric Practice 2010. [DOI: 10.1002/9781444323016.ch9] [Reference Citation Analysis]
|
| 305 |
Javier Brahm B, Rodrigo Quera P. Síndrome hepatorenal: patogénesis y tratamiento. Revista Médica Clínica Las Condes 2010;21:613-622. [DOI: 10.1016/s0716-8640(10)70577-0] [Reference Citation Analysis]
|
| 306 |
Angeli P, Morando F. Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepat Med 2010;2:87-98. [PMID: 24367209 DOI: 10.2147/hmer.s6918] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 307 |
Gonzalez SA, Trotter JF. Renal function and MELD: being direct is better. J Hepatol 2010;52:622-3. [PMID: 20347171 DOI: 10.1016/j.jhep.2010.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 308 |
Fukuhara T, Ikegami T, Morita K, Umeda K, Ueda S, Nagata S, Sugimachi K, Gion T, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y. Impact of preoperative serum sodium concentration in living donor liver transplantation. J Gastroenterol Hepatol 2010;25:978-84. [PMID: 20546453 DOI: 10.1111/j.1440-1746.2009.06162.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 309 |
Lim YS, Larson TS, Benson JT, Kamath PS, Kremers WK, Therneau TM, Kim WR. Serum sodium, renal function, and survival of patients with end-stage liver disease. J Hepatol 2010;52:523-8. [PMID: 20185195 DOI: 10.1016/j.jhep.2010.01.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 310 |
Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, Leandro G, Patch D, Burroughs AK. Terlipressin therapy for renal failure in cirrhosis. Eur J Gastroenterol Hepatol 2010;22:481-6. [PMID: 19952764 DOI: 10.1097/MEG.0b013e3283345524] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 311 |
Dobre M, Demirjian S, Sehgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol 2011;43:175-84. [PMID: 20306131 DOI: 10.1007/s11255-010-9725-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 312 |
Jenq CC, Tsai MH, Tian YC, Chang MY, Lin CY, Lien JM, Chen YC, Fang JT, Chen PC, Yang CW. Serum sodium predicts prognosis in critically ill cirrhotic patients. J Clin Gastroenterol 2010;44:220-6. [PMID: 19636261 DOI: 10.1097/MCG.0b013e3181aabbcd] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 313 |
Hsu CY, Lin HC, Huang YH, Su CW, Lee FY, Huo TI, Lee PC, Lee JY, Lee SD. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Dig Liver Dis 2010;42:137-42. [PMID: 19595648 DOI: 10.1016/j.dld.2009.06.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 314 |
Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576-84. [PMID: 19885875 DOI: 10.1002/hep.23286] [Cited by in Crossref: 206] [Cited by in F6Publishing: 189] [Article Influence: 15.8] [Reference Citation Analysis]
|
| 315 |
Dancygier H, Rogart JN. Approach to the Patient with Ascites. Clinical Hepatology 2010. [DOI: 10.1007/978-3-540-93842-2_54] [Reference Citation Analysis]
|
| 316 |
Hasper D, Berg T. Hepatorenal Syndrome. Management of Acute Kidney Problems 2010. [DOI: 10.1007/978-3-540-69441-0_31] [Reference Citation Analysis]
|
| 317 |
Dancygier H. Complications of Liver Cirrhosis. Clinical Hepatology 2010. [DOI: 10.1007/978-3-642-04519-6_26] [Reference Citation Analysis]
|
| 318 |
Macdonald AA, Ziegler J, Sinclair L. Nutritional Status in Liver Transplant Recipients. Topics in Clinical Nutrition 2010;25:20-6. [DOI: 10.1097/tin.0b013e3181d108ed] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 319 |
Cheng IK, Li FF. Hepatorenal Syndrome. Comprehensive Clinical Nephrology 2010. [DOI: 10.1016/b978-0-323-05876-6.00072-1] [Reference Citation Analysis]
|
| 320 |
Müller-marbach A, Häussinger D, Rump L, Vonend O. Das hepatorenale Syndrom. Nephrologe 2010;5:29-42. [DOI: 10.1007/s11560-009-0339-z] [Reference Citation Analysis]
|
| 321 |
Moreau R, Francoz C, Lebrec D, Durand F. Syndrome hépatorénal. Réanimation hépatosplanchnique 2010. [DOI: 10.1016/b978-2-8101-0186-3.50010-2] [Reference Citation Analysis]
|
| 322 |
Carithers RL, Mcclain CJ. Alcoholic Liver Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2010. [DOI: 10.1016/b978-1-4160-6189-2.00084-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 323 |
Davenport A. Extracorporeal support for patients with hepatic failure. Hemodial Int. 2003;7:256-263. [PMID: 19379373 DOI: 10.1046/j.1492-7535.2003.00046.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 324 |
Kiser TH, Maclaren R, Fish DN. Treatment of hepatorenal syndrome. Pharmacotherapy. 2009;29:1196-1211. [PMID: 19792993 DOI: 10.1592/phco.29.10.1196] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 325 |
Appenrodt B, Zielinski J, Brensing KA, Heller J, Sauerbruch T, Schepke M. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis. Eur J Gastroenterol Hepatol 2009;21:1428-32. [PMID: 19794309 DOI: 10.1097/MEG.0b013e32832ec16a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 326 |
Seo YS, Jung ES, An H, Kim JH, Jung YK, Kim JH, Yim HJ, Yeon JE, Byun KS, Kim CD, Ryu HS, Um SH. Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int 2009;29:1521-7. [PMID: 19725889 DOI: 10.1111/j.1478-3231.2009.02105.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 327 |
Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shihab FS, Marotta P, Cantarovich M, Eason JD, Wiesner RH, Ramsay MA, Garcia-Valdecasas JC, Neuberger JM, Feng S, Davis CL, Gonwa TA; International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009;15:S1-34. [PMID: 19877213 DOI: 10.1002/lt.21877] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 328 |
Huang HC, Lee FY, Huo TI. Major adverse events, pretransplant assessment and outcome prediction. J Gastroenterol Hepatol 2009;24:1716-24. [PMID: 20136958 DOI: 10.1111/j.1440-1746.2009.06025.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 329 |
Rochling FA, Zetterman RK. Management of Ascites: . Drugs 2009;69:1739-60. [DOI: 10.2165/11316390-000000000-00000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 330 |
Jacqmin S, Ghiglione S, Ozier Y. Le syndrome hépatorénal. Le Praticien en Anesthésie Réanimation 2009;13:262-272. [DOI: 10.1016/j.pratan.2009.07.004] [Reference Citation Analysis]
|
| 331 |
Kalil JR, Cerqueira LA, Barbosa DS, Motta MP, Nery MDS, Bittencourt PL. Poor outcomes with treatment of hepatorenal syndrome type 1 with splancnic vasoconstrictors and albumin: report of seven cases and review of the literature. Arq Gastroenterol 2009;46:214-8. [DOI: 10.1590/s0004-28032009000300014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 332 |
Dawwas MF, Lewsey JD, Watson CJ, Gimson AE. The Impact of Serum Potassium Concentration on Mortality After Liver Transplantation: A Cohort Multicenter Study. Transplantation 2009;88:402-10. [DOI: 10.1097/tp.0b013e3181aed8e4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 333 |
Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009;43:680-5. [PMID: 19238094 DOI: 10.1097/MCG.0b013e318188947c] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 334 |
Colmenero J, Castro-Narro G, Navasa M. [The value of MELD in the allocation of priority for liver transplantation candidates]. Gastroenterol Hepatol 2010;33:330-6. [PMID: 19631411 DOI: 10.1016/j.gastrohep.2009.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 335 |
Mackelaite L, Alsauskas ZC, Ranganna K. Renal failure in patients with cirrhosis. Med Clin North Am 2009;93:855-69, viii. [PMID: 19577118 DOI: 10.1016/j.mcna.2009.03.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 336 |
Xu X, Ling Q, Zhang M, Gao F, He Z, You J, Zheng S. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. Transplantation. 2009;87:1514-1519. [PMID: 19461488 DOI: 10.1097/tp.0b013e3181a4430b] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 337 |
Bansal S, Lindenfeld J, Schrier RW. Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist? Circ: Heart Failure 2009;2:370-6. [DOI: 10.1161/circheartfailure.108.821199] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 338 |
Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009;104:1802-29. [PMID: 19455106 DOI: 10.1038/ajg.2009.191] [Cited by in Crossref: 177] [Cited by in F6Publishing: 179] [Article Influence: 12.6] [Reference Citation Analysis]
|
| 339 |
Minemura M, Tajiri K, Shimizu Y. Systemic abnormalities in liver disease. World J Gastroenterol 2009;15:2960-74. [PMID: 19554648 DOI: 10.3748/wjg.15.2960] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 340 |
Kayali Z, Herring J, Baron P, Franco E, Ojogho O, Smith J, Watkins G, Smith D, Lamin V, Hoang T, Sharma R, Mathahs M, Sowers L, Brown KE, Schmidt WN. Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction. J Gastroenterol Hepatol 2009;24:1030-7. [PMID: 19226382 DOI: 10.1111/j.1440-1746.2008.05757.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 341 |
Poordad FF, Sigal SH, Brown RS. Pathophysiologic basis for the medical management of portal hypertension. Expert Opin Pharmacother. 2009;10:453-467. [PMID: 19191681 DOI: 10.1517/14656560802707853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 342 |
Kim JH, Kim JH, Choi JH, Kim CH, Jung YK, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Scand J Gastroenterol 2009;44:346-57. [PMID: 18991165 DOI: 10.1080/00365520802530838] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 343 |
Yun BC, Kim WR, Benson JT, Biggins SW, Therneau TM, Kremers WK, Rosen CB, Klintmalm GB. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 2009;49:1610-5. [PMID: 19402063 DOI: 10.1002/hep.22846] [Cited by in Crossref: 103] [Cited by in F6Publishing: 86] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 344 |
Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study. Dig Liver Dis 2009;41:298-302. [PMID: 19158001 DOI: 10.1016/j.dld.2008.09.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 345 |
Karwa R, Woodis CB. Midodrine and Octreotide in Treatment of Cirrhosis-Related Hemodynamic Complications. Ann Pharmacother 2009;43:692-9. [DOI: 10.1345/aph.1l373] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 346 |
Lodhia N, Kader M, Mayes T, Mantry P, Maliakkal B. Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis. World J Gastroenterol 2009; 15(12): 1459-1464 [PMID: 19322918 DOI: 10.3748/wjg.15.1459] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 347 |
Hepatorenal syndrome. Hepatology Textbook and Atlas. [DOI: 10.1007/978-3-540-76839-5_17] [Reference Citation Analysis]
|
| 348 |
Hackworth WA, Sanyal AJ. Review: Vasoconstrictors for the treatment of portal hypertension. Therap Adv Gastroenterol 2009;2:119-31. [DOI: 10.1177/1756283x09102330] [Reference Citation Analysis]
|
| 349 |
Argo CK, Balogun RA. Blood products, volume control, and renal support in the coagulopathy of liver disease. Clin Liver Dis 2009;13:73-85. [PMID: 19150312 DOI: 10.1016/j.cld.2008.09.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 350 |
Arroyo V, Fernández J. Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome. Critical Care Nephrology 2009. [DOI: 10.1016/b978-1-4160-4252-5.50173-8] [Reference Citation Analysis]
|
| 351 |
Wong F. Management of ascites and hepatorenal syndrome. Chronic Inflammation of Liver and Gut 2009. [DOI: 10.1007/978-1-4020-9353-1_19] [Reference Citation Analysis]
|
| 352 |
Berl T, Schrier RW. Vasopressin Antagonists in Physiology and Disease. Textbook of Nephro-Endocrinology 2009. [DOI: 10.1016/b978-0-12-373870-7.00018-1] [Reference Citation Analysis]
|
| 353 |
Andrikos E, Balafa O. Pharmacological Treatment for Hepatorenal Syndrome. Critical Care Nephrology 2009. [DOI: 10.1016/b978-1-4160-4252-5.50204-5] [Reference Citation Analysis]
|
| 354 |
Navarro VJ, Rossi S, Herrine SK. HEPATIC CIRRHOSIS. Pharmacology and Therapeutics 2009. [DOI: 10.1016/b978-1-4160-3291-5.50038-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 355 |
Somberg JC, Molnar J. Therapeutic Approaches to the Treatment of Edema and Ascites: The Use of Diuretics. American Journal of Therapeutics 2009;16:98-101. [DOI: 10.1097/mjt.0b013e318196082e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 356 |
Palma HA, Correa-rotter R. Diálisis peritoneal en situaciones especiales. Tratado de diálisis peritoneal 2009. [DOI: 10.1016/b978-84-8086-394-0.50027-7] [Reference Citation Analysis]
|
| 357 |
Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064-77. [PMID: 19003880 DOI: 10.1002/hep.22605] [Cited by in Crossref: 438] [Cited by in F6Publishing: 371] [Article Influence: 29.2] [Reference Citation Analysis]
|
| 358 |
Gentilini P, La Villa G. Liver-kidney pathophysiological interrelationships in liver diseases. Dig Liver Dis 2008;40:909-19. [PMID: 18621592 DOI: 10.1016/j.dld.2008.05.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 359 |
Schrier RW. Vasopressin and aquaporin 2 in clinical disorders of water homeostasis. Semin Nephrol 2008;28:289-96. [PMID: 18519089 DOI: 10.1016/j.semnephrol.2008.03.009] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 360 |
Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269-82. [PMID: 19669378 DOI: 10.1007/s12072-008-9106-x] [Cited by in Crossref: 578] [Cited by in F6Publishing: 626] [Article Influence: 38.5] [Reference Citation Analysis]
|
| 361 |
Huo TI, Lin HC, Hsia CY, Huang YH, Wu JC, Chiang JH, Chiou YY, Lui WY, Lee PC, Lee SD. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis 2008;40:882-9. [PMID: 18339595 DOI: 10.1016/j.dld.2008.01.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 362 |
Kim SU, Han KH, Nam CM, Park JY, Kim DY, Chon CY, Ahn SH. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol 2008;23:1722-7. [PMID: 18717757 DOI: 10.1111/j.1440-1746.2008.05510.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 363 |
Bambha KM, Biggins SW. Inequities of the Model for End-Stage Liver Disease: an examination of current components and future additions. Curr Opin Organ Transplant. 2008;13:227-233. [PMID: 18685308 DOI: 10.1097/MOT.0b013e3282ff84c7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 364 |
Testro AG, Wongseelashote S, Angus PW, Gow PJ. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol 2008;23:1535-40. [PMID: 17784863 DOI: 10.1111/j.1440-1746.2007.05176.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 365 |
Cai C, Chen H, Lu M, Chen G. Model for end-stage liver disease-sodium predicts prognosis in patients with chronic severe hepatitis B: . Chinese Medical Journal 2008;121:2065-9. [DOI: 10.1097/00029330-200810020-00023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 366 |
Munoz SJ. The hepatorenal syndrome. Med Clin North Am. 2008;92:813-37, viii-ix. [PMID: 18570944 DOI: 10.1016/j.mcna.2008.03.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 367 |
Wong F. Hepatorenal syndrome: current management. Curr Gastroenterol Rep 2008;10:22-9. [PMID: 18417039 DOI: 10.1007/s11894-008-0005-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 368 |
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-1026. [PMID: 18768945 DOI: 10.1056/nejmoa080120910.1053/jhep.2001.22172] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 369 |
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-1026. [PMID: 18768945 DOI: 10.1056/nejmoa0801209] [Cited by in Crossref: 877] [Cited by in F6Publishing: 926] [Article Influence: 58.5] [Reference Citation Analysis]
|
| 370 |
Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008;48:1002-10. [PMID: 18671303 DOI: 10.1002/hep.22418] [Cited by in Crossref: 210] [Cited by in F6Publishing: 202] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 371 |
Bonney GK, Aldouri A, Attia M, Lodge PA, Toogood GJ, Pollard SG, Prasad R. Outcomes in right liver lobe transplantation: a matched pair analysis. Transpl Int 2008;21:1045-51. [PMID: 18662370 DOI: 10.1111/j.1432-2277.2008.00722.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 372 |
Dong MH, Saab S. Complications of cirrhosis. Dis Mon 2008;54:445-56. [PMID: 18570914 DOI: 10.1016/j.disamonth.2008.03.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 373 |
Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689-97. [PMID: 18557715 DOI: 10.1111/j.1572-0241.2008.01828.x] [Cited by in Crossref: 182] [Cited by in F6Publishing: 190] [Article Influence: 12.1] [Reference Citation Analysis]
|
| 374 |
Mehta RL, Cantarovich F, Shaw A, Hoste E, Murray P. Pharmacologic approaches for volume excess in acute kidney injury (AKI). Int J Artif Organs 2008;31:127-44. [PMID: 18311729 DOI: 10.1177/039139880803100206] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 375 |
Herrera JL. Complications of Cirrhosis. Practical Management of Liver Diseases 2008. [DOI: 10.1017/cbo9780511547416.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 376 |
Carithers RL. Liver Transplantation. Practical Management of Liver Diseases 2008. [DOI: 10.1017/cbo9780511547416.015] [Reference Citation Analysis]
|
| 377 |
Lautrette A, Liotier J, Deteix P, Souweine B. [Hepatorenal syndrome]. Nephrol Ther 2009;5:150-6. [PMID: 18514053 DOI: 10.1016/j.nephro.2008.03.005] [Reference Citation Analysis]
|
| 378 |
Huo TI, Lin HC, Huo SC, Lee PC, Wu JC, Lee FY, Hou MC, Lee SD. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis. Liver Transpl 2008;14:837-44. [PMID: 18508377 DOI: 10.1002/lt.21439] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 379 |
Döhler KD, Meyer M. Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage. Best Practice & Research Clinical Anaesthesiology 2008;22:335-50. [DOI: 10.1016/j.bpa.2008.02.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 380 |
Cárdenas A, Ginès P. [Dilutional hyponatremia, hepatorenal syndrome and liver transplantation]. Gastroenterol Hepatol. 2008;31:29-36. [PMID: 18218278 DOI: 10.1157/13114568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 381 |
Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology 2008;134:1715-28. [PMID: 18471549 DOI: 10.1053/j.gastro.2008.03.007] [Cited by in Crossref: 245] [Cited by in F6Publishing: 259] [Article Influence: 16.3] [Reference Citation Analysis]
|
| 382 |
Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-9. [PMID: 18471512 DOI: 10.1053/j.gastro.2008.02.024] [Cited by in Crossref: 411] [Cited by in F6Publishing: 436] [Article Influence: 27.4] [Reference Citation Analysis]
|
| 383 |
Lim JK, Groszmann RJ. Vasoconstrictor therapy for the hepatorenal syndrome. Gastroenterology 2008;134:1608-11. [PMID: 18471529 DOI: 10.1053/j.gastro.2008.03.034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 384 |
Huo TI, Lee SD, Lin HC. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int 2008;28:606-13. [PMID: 18433390 DOI: 10.1111/j.1478-3231.2008.01727.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 385 |
Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-8. [PMID: 18471513 DOI: 10.1053/j.gastro.2008.02.014] [Cited by in Crossref: 443] [Cited by in F6Publishing: 469] [Article Influence: 29.5] [Reference Citation Analysis]
|
| 386 |
McCormick PA, Donnelly C. Management of hepatorenal syndrome. Pharmacol Ther. 2008;119:1-6. [PMID: 18539334 DOI: 10.1016/j.pharmthera.2008.02.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 387 |
Manning JJ, Hislop WS, McPeake JR. The management of renal failure in patients with liver disease. Experiences from a district general hospital. Scott Med J 2008;53:25-9. [PMID: 18422206 DOI: 10.1258/RSMSMJ.53.1.25] [Reference Citation Analysis]
|
| 388 |
Genzini T, Torricelli FC. Hepatorenal syndrome: an update. Sao Paulo Med J. 2007;125:50-56. [PMID: 17505686 DOI: 10.1590/S1516-31802007000100010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 389 |
Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48 Suppl 1:S93-103. [PMID: 18304678 DOI: 10.1016/j.jhep.2008.01.010] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 390 |
Mathur S, Gane EJ, McCall JL, Plank LD. Serum sodium and hydration status predict transplant-free survival independent of MELD score in patients with cirrhosis. J Gastroenterol Hepatol 2008;23:239-43. [PMID: 17489965 DOI: 10.1111/j.1440-1746.2007.04891.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 391 |
Beckebaum S, Cicinnati V, Frilling A. Pre-Transplantation MAnagement Issue. Liver and Biliary Tract Surgery. [DOI: 10.1007/978-3-211-49277-2_48] [Reference Citation Analysis]
|
| 392 |
Ginès P, Schrier RW. Renal Failure in Cirrhosis. Seldin and Giebisch's The Kidney 2008. [DOI: 10.1016/b978-012088488-9.50082-6] [Reference Citation Analysis]
|
| 393 |
Pépin M, Ginès P. Management of Hepatorenal Syndrome. Therapy in Nephrology & Hypertension 2008. [DOI: 10.1016/b978-141605484-9.50007-1] [Reference Citation Analysis]
|
| 394 |
Schrier RW. Molecular mechanisms of clinical concentrating and diluting disorders. Prog Brain Res 2008;170:539-50. [PMID: 18655907 DOI: 10.1016/S0079-6123(08)00441-X] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 395 |
Angeli P. Hepatorenal Syndrome. Intensive Care Medicine. [DOI: 10.1007/0-387-35096-9_61] [Reference Citation Analysis]
|
| 396 |
Di Campli C, Zocco MA, Saulnier N, Grieco A, Rapaccini G, Addolorato G, Rumi C, Santoliquido A, Leone G, Gasbarrini G, Gasbarrini A. Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis 2007;39:1071-6. [PMID: 17964871 DOI: 10.1016/j.dld.2007.08.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 397 |
Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol 2007; 13(42): 5552-5559 [PMID: 17948928 DOI: 10.3748/wjg.v13.i42.5552] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 86] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 398 |
Baccaro ME, Guevara M. [Hepatorenal syndrome]. Gastroenterol Hepatol 2007;30:548-54. [PMID: 17980134 DOI: 10.1157/13111697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 399 |
Jacqmin S, Ozier Y, Sogni P. Syndrome hépato-rénal. Le point sur …. [DOI: 10.1007/978-2-287-71152-7_11] [Reference Citation Analysis]
|
| 400 |
Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007;47:499-505. [PMID: 17560680 DOI: 10.1016/j.jhep.2007.04.010] [Cited by in Crossref: 216] [Cited by in F6Publishing: 230] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 401 |
Shusterman B, Mchedishvili G, Rosner MH. Outcomes for hepatorenal syndrome and acute kidney injury in patients undergoing liver transplantation: a single-center experience. Transplant Proc 2007;39:1496-500. [PMID: 17580171 DOI: 10.1016/j.transproceed.2007.01.087] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 402 |
Wong VW, Chim AM, Wong GL, Sung JJ, Chan HL. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl 2007;13:1228-35. [PMID: 17763399 DOI: 10.1002/lt.21222] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 403 |
Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8. [PMID: 17389705 DOI: 10.1136/gut.2006.107789] [Cited by in Crossref: 136] [Cited by in F6Publishing: 285] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 404 |
Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-24. [PMID: 17854593 DOI: 10.1053/j.gastro.2007.06.065] [Cited by in Crossref: 502] [Cited by in F6Publishing: 525] [Article Influence: 31.4] [Reference Citation Analysis]
|
| 405 |
Turban S, Thuluvath PJ, Atta MG. Hepatorenal syndrome. World J Gastroenterol 2007; 13(30): 4046-4055 [PMID: 17696221 DOI: 10.3748/wjg.v13.i30.4046] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 406 |
Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, Peck-Radosavljevic M, Gridelli B, Bosch J. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007;13:1174-80. [PMID: 17663415 DOI: 10.1002/lt.21197] [Cited by in Crossref: 175] [Cited by in F6Publishing: 165] [Article Influence: 10.9] [Reference Citation Analysis]
|
| 407 |
Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl 2007;13:1115-24. [PMID: 17663412 DOI: 10.1002/lt.21154] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 408 |
Biggins SW. Beyond the numbers: rational and ethical application of outcome models for organ allocation in liver transplantation. Liver Transpl 2007;13:1080-3. [PMID: 17663407 DOI: 10.1002/lt.21210] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 409 |
Taddei TH, Strazzabosco M. Hepatic venous pressure gradient (HVPG), serum sodium (SNa), and model of end-stage liver disease score (MELD): prognostic significance and correlations. J Clin Gastroenterol 2007;41:641-3. [PMID: 17667045 DOI: 10.1097/MCG.0b013e318051741d] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 410 |
Gülberg V, Gerbes A. Aszites und hepatorenales Syndrom. Gastroenterologe 2007;2:246-250. [DOI: 10.1007/s11377-007-0087-4] [Reference Citation Analysis]
|
| 411 |
Ruiz R, Barri YM, Jennings LW, Chinnakotla S, Goldstein RM, Levy MF, McKenna GJ, Randall HB, Sanchez EQ, Klintmalm GB. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl 2007;13:838-43. [PMID: 17539003 DOI: 10.1002/lt.21149] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 412 |
Hardy S, Kleinman RE. Cirrhosis and Chronic Liver Failure. Liver Disease in Children 2007. [DOI: 10.1017/cbo9780511547409.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 413 |
Grewal P, Martin P. Pretransplant management of the cirrhotic patient. Clin Liver Dis 2007;11:431-49. [PMID: 17606216 DOI: 10.1016/j.cld.2007.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 414 |
Tandon P, Bain VG, Tsuyuki RT, Klarenbach S. Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials. Aliment Pharmacol Ther 2007;25:1017-28. [PMID: 17439502 DOI: 10.1111/j.1365-2036.2007.03303.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 415 |
McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R; Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-33. [PMID: 17444847 DOI: 10.1111/j.1440-1746.2007.04883.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 416 |
Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46:935-46. [PMID: 17391801 DOI: 10.1016/j.jhep.2007.02.001] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 417 |
Besso J, Pru C, Padron J, Plaz J. Hepatorenal Syndrome. Intensive and Critical Care Medicine. [DOI: 10.1007/88-470-0350-4_3] [Reference Citation Analysis]
|
| 418 |
Young AL, Rajagenashan R, Asthana S, Peters CJ, Toogood GJ, Davies MH, Lodge JPA, Pollard SG, Rajendra Prasad K. The value of MELD and sodium in assessing potential liver transplant recipients in the United Kingdom. Transplant Int 2007;20:331-7. [DOI: 10.1111/j.1432-2277.2006.00441.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 419 |
Baccaro ME, Guevara M, Rodés J. Ascites. The Foundation Years 2007;3:57-60. [DOI: 10.1016/j.mpfou.2007.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 420 |
Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007;45:797-805. [PMID: 17326206 DOI: 10.1002/hep.21563] [Cited by in Crossref: 1059] [Cited by in F6Publishing: 942] [Article Influence: 66.2] [Reference Citation Analysis]
|
| 421 |
Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52:742-8. [PMID: 17235705 DOI: 10.1007/s10620-006-9312-0] [Cited by in Crossref: 128] [Cited by in F6Publishing: 132] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 422 |
Baccaro ME, Guevara M, Rodés J. Ascites. Medicine 2007;35:104-107. [DOI: 10.1016/j.mpmed.2006.11.005] [Reference Citation Analysis]
|
| 423 |
Cárdenas A, Arroyo V. Management of ascites and hepatic hydrothorax. Best Pract Res Clin Gastroenterol 2007;21:55-75. [PMID: 17223497 DOI: 10.1016/j.bpg.2006.07.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 424 |
Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:111-23. [PMID: 17223500 DOI: 10.1016/j.bpg.2006.10.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 425 |
Susla GM, Atkinson AJ. Effect of Liver Disease on Pharmacokinetics. Principles of Clinical Pharmacology. Elsevier; 2007. pp. 73-87. [DOI: 10.1016/b978-012369417-1/50047-x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 426 |
Prieto M, Aguilera V, Berenguer M, Pina R, Benlloch S. Selección de candidatos para trasplante hepático. Gastroenterología y Hepatología 2007;30:42-53. [DOI: 10.1157/13097451] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 427 |
MacAulay J, Thompson K, Kiberd BA, Barnes DC, Peltekian KM. Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction: are the equations for estimating renal function better? Can J Gastroenterol. 2006;20:521-526. [PMID: 16955148 DOI: 10.1155/2006/858053] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 428 |
Angeli P, Wong F, Watson H, Ginès P; CAPPS Investigators. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006;44:1535-42. [PMID: 17133458 DOI: 10.1002/hep.21412] [Cited by in Crossref: 275] [Cited by in F6Publishing: 228] [Article Influence: 16.2] [Reference Citation Analysis]
|
| 429 |
Biggins SW, Colquhoun S, Gish RG, Runyon BA. Model for end-stage liver disease (MELD) exception for ascites. Liver Transpl 2006;12:S88-90. [PMID: 17123288 DOI: 10.1002/lt.20963] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 430 |
Ahya SN, José Soler M, Levitsky J, Batlle D. Acid-Base and Potassium Disorders in Liver Disease. Seminars in Nephrology 2006;26:466-70. [DOI: 10.1016/j.semnephrol.2006.11.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 431 |
Planas R, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, Galeras JA, Giménez MD, Santos J, Cirera I, Morillas RM, Coll S, Solà R. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4:1385-94. [PMID: 17081806 DOI: 10.1016/j.cgh.2006.08.007] [Cited by in Crossref: 272] [Cited by in F6Publishing: 219] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 432 |
Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2006;CD005162. [PMID: 17054242 DOI: 10.1002/14651858.cd005162.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 433 |
Ponte B, Spahr L, Martin P. La prise en charge du syndrome hépato-rénal en réanimation. Le Praticien en Anesthésie Réanimation 2006;10:353-358. [DOI: 10.1016/s1279-7960(06)75605-4] [Reference Citation Analysis]
|
| 434 |
Yu JW, Wang GQ, Li SC. Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system. J Gastroenterol Hepatol 2006;21:1519-24. [PMID: 16928211 DOI: 10.1111/j.1440-1746.2006.04510.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 435 |
Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006;24:935-44. [PMID: 16948805 DOI: 10.1111/j.1365-2036.2006.03086.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 436 |
Debray D, Yousef N, Durand P. New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients. Paediatr Drugs 2006;8:1-13. [PMID: 16494508 DOI: 10.2165/00148581-200608010-00001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 437 |
Verma S, Ajudia K, Mendler M, Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006;51:1637-43. [PMID: 16927139 DOI: 10.1007/s10620-006-9099-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 438 |
Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006;26:834-9. [PMID: 16911466 DOI: 10.1111/j.1478-3231.2006.01302.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 439 |
Han MK, Hyzy R. Advances in critical care management of hepatic failure and insufficiency: . Critical Care Medicine 2006;34:S225-31. [DOI: 10.1097/01.ccm.0000231882.85350.71] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 440 |
Cárdenas A, Ginès P. Therapy insight: Management of hepatorenal syndrome. Nat Clin Pract Gastroenterol Hepatol. 2006;3:338-348. [PMID: 16741553 DOI: 10.1038/ncpgasthep0517] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 441 |
López-Parra M, Telleria N, Titos E, Planagumà A, González-Périz A, Arroyo V, Rodés J, Clària J. Gene expression profiling of renal dysfunction in rats with experimental cirrhosis. J Hepatol 2006;45:221-9. [PMID: 16644059 DOI: 10.1016/j.jhep.2006.02.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 442 |
Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006;1:1066-1079. [PMID: 17699328 DOI: 10.2215/cjn.01340406] [Cited by in Crossref: 165] [Cited by in F6Publishing: 184] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 443 |
Rivera-Huizar S, Rincón-Sánchez AR, Covarrubias-Pinedo A, Islas-Carbajal MC, Gabriel-Ortíz G, Pedraza-Chaverrí J, Alvarez-Rodríguez A, Meza-García E, Armendáriz-Borunda J. Renal dysfunction as a consequence of acute liver damage by bile duct ligation in cirrhotic rats. Exp Toxicol Pathol. 2006;58:185-195. [PMID: 16829063 DOI: 10.1016/j.etp.2006.05.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 444 |
Chan HL, Chim AM, Lau JT, Hui AY, Wong VW, Sung JJ. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol 2006;101:1516-23. [PMID: 16863555 DOI: 10.1111/j.1572-0241.2006.00659.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 445 |
Natarajan SK, Basivireddy J, Ramachandran A, Thomas S, Ramamoorthy P, Pulimood AB, Jacob M, Balasubramanian KA. Renal damage in experimentally-induced cirrhosis in rats: Role of oxygen free radicals. Hepatology 2006;43:1248-56. [PMID: 16729302 DOI: 10.1002/hep.21179] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 446 |
Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol. 2006;17:1820-1832. [PMID: 16738014 DOI: 10.1681/asn.2006030240] [Cited by in Crossref: 128] [Cited by in F6Publishing: 137] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 447 |
Sandhu BS, Sanyal AJ. Hepatorenal syndrome. Curr Treat Options Gastroenterol 2005;8:443-50. [PMID: 16313861 DOI: 10.1007/s11938-005-0030-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 448 |
Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-60. [PMID: 16697729 DOI: 10.1053/j.gastro.2006.02.010] [Cited by in Crossref: 487] [Cited by in F6Publishing: 513] [Article Influence: 28.6] [Reference Citation Analysis]
|
| 449 |
Cárdenas A, Gines P. Hepatorenal syndrome. Clin Liver Dis 2006;10:371-85, ix-x. [PMID: 16971267 DOI: 10.1016/j.cld.2006.05.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 450 |
Londoño MC, Guevara M, Rimola A, Navasa M, Taurà P, Mas A, García-Valdecasas JC, Arroyo V, Ginès P. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006;130:1135-43. [PMID: 16618408 DOI: 10.1053/j.gastro.2006.02.017] [Cited by in Crossref: 139] [Cited by in F6Publishing: 145] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 451 |
Chiu A, Fan ST. Use of MARS in Hepatorenal Syndrome — A Local Perspective. Hong Kong Journal of Nephrology 2006;8:5-9. [DOI: 10.1016/s1561-5413(09)60223-4] [Reference Citation Analysis]
|
| 452 |
Bernal W, Wendon J. Cell-Free Artificial Liver Support: Design of Appropriate Clinical Studies. Therapher Dial 2006;10:175-9. [DOI: 10.1111/j.1744-9987.2006.00360.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 453 |
Esrailian E, Runyon BA. Alcoholic cirrhosis-associated hepatorenal syndrome treated with vasoactive agents. Nat Rev Nephrol 2006;2:169-72. [DOI: 10.1038/ncpneph0114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 454 |
Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006;43:385-94. [PMID: 16496352 DOI: 10.1002/hep.21094] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 455 |
Brünnler T, Mandraka F, Langgartner J. Terlipressin—. Intensivmed 2006;43:82-82. [DOI: 10.1007/s00390-006-0691-4] [Reference Citation Analysis]
|
| 456 |
Biancofiore G, Pucci L, Cerutti E, Penno G, Pardini E, Esposito M, Bindi L, Pelati E, Romanelli A, Triscornia S, Salvadorini MP, Stratta C, Lanfranco G, Pellegrini G, Del Prato S, Salizzoni M, Mosca F, Filipponi F. Cystatin C as a marker of renal function immediately after liver transplantation. Liver Transpl 2006;12:285-91. [PMID: 16447198 DOI: 10.1002/lt.20657] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 457 |
Sargent S. The management and nursing care of cirrhotic ascites. British Journal of Nursing 2006;15:212-9. [DOI: 10.12968/bjon.2006.15.4.20547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 458 |
Di Campli C, Santoro MC, Gaspari R, Merra G, Zileri Dal Verme L, Zocco MA, Piscaglia AC, Di Gioacchino G, Novi M, Santoliquido A. Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure. Transplant Proc. 2005;37:2547-2550. [PMID: 16182739 DOI: 10.1016/j.transproceed.2005.06.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 459 |
Hepatorenal syndrome. Hepatology Principles and Practice. [DOI: 10.1007/3-540-28977-1_17] [Reference Citation Analysis]
|
| 460 |
Demırtaş S, Can M, Yarpuzlu A. Hepatorenal syndrome / Hepatorenales Syndrom. LaboratoriumsMedizin 2006;30:272-279. [DOI: 10.1515/jlm.2006.998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 461 |
Pillebout E. Syndrome hépatorénal. EMC - Néphrologie 2006;1:1-7. [DOI: 10.1016/s1762-0945(11)58254-3] [Reference Citation Analysis]
|
| 462 |
Garcia-tsao G. Ascites. Zakim and Boyer's Hepatology 2006. [DOI: 10.1016/b978-1-4160-3258-8.50024-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 463 |
Sargent S, Martin W. Renal dysfunction in liver cirrhosis. Br J Nurs 2006;15:12-16. [DOI: 10.12968/bjon.2006.15.1.20302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 464 |
Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F, Antona C, Brollo L, Franchin M, Cillo U, Merkel C, Gatta A. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006;23:75-84. [PMID: 16393283 DOI: 10.1111/j.1365-2036.2006.02706.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 465 |
Arroyo V, Ginès P, Guevara M, Rodés J. Renal Dysfunction in Cirrhosis: Pathophysiology, Clinical Features and Therapy. Zakim and Boyer's Hepatology 2006. [DOI: 10.1016/b978-1-4160-3258-8.50027-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 466 |
Angeli P. Hepatorenal Syndrome. Yearbook of Intensive Care and Emergency Medicine 2006. [DOI: 10.1007/3-540-33396-7_61] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 467 |
Péron JM, Bureau C, Gonzalez L, Garcia-Ricard F, de Soyres O, Dupuis E, Alric L, Pourrat J, Vinel JP. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 2005;100:2702-7. [PMID: 16393223 DOI: 10.1111/j.1572-0241.2005.00271.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 468 |
Terra C, Guevara M, Torre A, Gilabert R, Fernández J, Martín-Llahí M, Baccaro ME, Navasa M, Bru C, Arroyo V, Rodés J, Ginès P. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005;129:1944-53. [PMID: 16344063 DOI: 10.1053/j.gastro.2005.09.024] [Cited by in Crossref: 185] [Cited by in F6Publishing: 197] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 469 |
Bloom RD, Goldberg LR, Wang AY, Faust TW, Kotloff RM. An Overview of Solid Organ Transplantation. Clinics in Chest Medicine 2005;26:529-43. [DOI: 10.1016/j.ccm.2005.06.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 470 |
Mendez CM, McClain CJ, Marsano LS. Albumin therapy in clinical practice. Nutr Clin Pract 2005;20:314-20. [PMID: 16207669 DOI: 10.1177/0115426505020003314] [Cited by in Crossref: 107] [Cited by in F6Publishing: 112] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 471 |
Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant. 2006;21:478-482. [PMID: 16249201 DOI: 10.1093/ndt/gfi212] [Cited by in Crossref: 110] [Cited by in F6Publishing: 118] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 472 |
Howard CS, Teitelbaum I. Renal replacement therapy in patients with chronic liver disease. Semin Dial. 2005;18:212-216. [PMID: 15934968 DOI: 10.1111/j.1525-139x.2005.18315.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 473 |
Wright AS, Rikkers LF. Current management of portal hypertension. J Gastrointest Surg 2005;9:992-1005. [PMID: 16137597 DOI: 10.1016/j.gassur.2004.09.028] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 474 |
Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, Milicua JM, Jiménez W, Arroyo V. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-47. [PMID: 15977202 DOI: 10.1002/hep.20766] [Cited by in Crossref: 407] [Cited by in F6Publishing: 340] [Article Influence: 22.6] [Reference Citation Analysis]
|
| 475 |
Zaza S, Bonny O, Liaudet L. Le syndrome hépatorénal chez le patient cirrhotique. Néphrologie & Thérapeutique 2005;1:174-82. [DOI: 10.1016/j.nephro.2005.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 476 |
Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005;20:1813-20. [PMID: 15956066 DOI: 10.1093/ndt/gfh930] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 477 |
Murray KF, Carithers RL Jr; AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005;41:1407-32. [PMID: 15880505 DOI: 10.1002/hep.20704] [Cited by in Crossref: 553] [Cited by in F6Publishing: 496] [Article Influence: 30.7] [Reference Citation Analysis]
|
| 478 |
Brünnler T, Mandraka F, Langgartner J. Terlipressin—. Intensivmed 2005;42:468-478. [DOI: 10.1007/s00390-005-0603-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 479 |
Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, Rodés J, Ginès P. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282-9. [PMID: 15834937 DOI: 10.1002/hep.20687] [Cited by in Crossref: 261] [Cited by in F6Publishing: 230] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 480 |
Pham PT, Pham PC, Rastogi A, Wilkinson AH. Review article: current management of renal dysfunction in the cirrhotic patient. Aliment Pharmacol Ther 2005;21:949-61. [PMID: 15813830 DOI: 10.1111/j.1365-2036.2005.02357.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 481 |
Capling RK, Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail. 2004;26:563-568. [PMID: 15526916 DOI: 10.1081/jdi-200035988] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 482 |
Vaughan RB, Chin-dusting JP. Current pharmacotherapy in the management of cirrhosis: focus on the hyperdynamic circulation. Expert Opinion on Pharmacotherapy 2005;4:625-37. [DOI: 10.1517/14656566.4.5.625] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 483 |
Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-43. [PMID: 15719386 DOI: 10.1002/lt.20329] [Cited by in Crossref: 305] [Cited by in F6Publishing: 234] [Article Influence: 16.9] [Reference Citation Analysis]
|
| 484 |
Nietsch HH. Management of portal hypertension. J Clin Gastroenterol 2005;39:232-6. [PMID: 15718866 DOI: 10.1097/01.mcg.0000152783.22266.35] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 485 |
Henriksen JH. Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis. Scand J Clin Lab Invest. 2004;64:523-533. [PMID: 15370457 DOI: 10.1080/00365510410002788] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 486 |
Cárdenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol 2005;100:460-7. [PMID: 15667508 DOI: 10.1111/j.1572-0241.2005.40952.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 487 |
Liotier J, Souweine B, Deteix P. Syndrome hépatorénal. EMC - Néphrologie 2005;2:1-7. [DOI: 10.1016/j.emcnep.2004.11.001] [Reference Citation Analysis]
|
| 488 |
Sonoda J, Chong LW, Downes M, Barish GD, Coulter S, Liddle C, Lee CH, Evans RM. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc Natl Acad Sci U S A 2005;102:2198-203. [PMID: 15671183 DOI: 10.1073/pnas.0409481102] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 489 |
Gluud L, Kjaer M, Taastroem A, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database of Systematic Reviews 2005. [DOI: 10.1002/14651858.cd005162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 490 |
Sharma P, Vargas HE, Rakela J. Monitoring and Care of the Patient Before Liver Transplantation. Transplantation of the Liver 2005. [DOI: 10.1016/b978-0-7216-0118-2.50037-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 491 |
Guevara M, Ginès P. Hepatorenal syndrome. Dig Dis 2005;23:47-55. [PMID: 15920325 DOI: 10.1159/000084725] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 492 |
Mai ML, Yip DS, Keller CA, Gonwa TA. Pretransplantation Evaluation: Pulmonary, Cardiac, and Renal. Transplantation of the Liver 2005. [DOI: 10.1016/b978-0-7216-0118-2.50033-1] [Reference Citation Analysis]
|
| 493 |
Kbalid SK, Garcia-tsao G. Ascites. Portal Hypertension 2005. [DOI: 10.1007/978-1-59259-885-4_19] [Reference Citation Analysis]
|
| 494 |
Bergheim I, McClain CJ, Arteel GE. Treatment of alcoholic liver disease. Dig Dis 2005;23:275-84. [PMID: 16508292 DOI: 10.1159/000090175] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 495 |
Pham PT, Pham PT, Wilkinson AH. Renal Failure in Adult Liver Transplant Recipients. Transplantation of the Liver. Elsevier; 2005. pp. 891-914. [DOI: 10.1016/b978-0-7216-0118-2.50065-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 496 |
Veis JH. Alcohol, Alcoholism and Effects on the Kidney and Kidney Disease. Comprehensive Handbook of Alcohol Related Pathology 2005. [DOI: 10.1016/b978-012564370-2/50043-x] [Reference Citation Analysis]
|
| 497 |
Moore K. Diagnosis and Management of the Hepatorenal Syndrome. Portal Hypertension 2005. [DOI: 10.1007/978-1-59259-885-4_22] [Reference Citation Analysis]
|
| 498 |
Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41:32-9. [PMID: 15690479 DOI: 10.1002/hep.20517] [Cited by in Crossref: 299] [Cited by in F6Publishing: 229] [Article Influence: 16.6] [Reference Citation Analysis]
|
| 499 |
Cardenas A, Ginès P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 2005;42 Suppl:S124-33. [PMID: 15777567 DOI: 10.1016/j.jhep.2004.12.007] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 500 |
Serra MA, Puchades MJ, Rodríguez F, Escudero A, del Olmo JA, Wassel AH, Rodrigo JM. Clinical value of increased serum creatinine concentration as predictor of short-term outcome in decompensated cirrhosis. Scand J Gastroenterol 2004;39:1149-53. [PMID: 15545175 DOI: 10.1080/00365520410008024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 501 |
Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-10. [PMID: 15382176 DOI: 10.1002/hep.20405] [Cited by in Crossref: 35] [Cited by in F6Publishing: 97] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 502 |
Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-10. [PMID: 15382176 DOI: 10.1002/hep.20405] [Cited by in Crossref: 376] [Cited by in F6Publishing: 267] [Article Influence: 19.8] [Reference Citation Analysis]
|
| 503 |
Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, Macías MA, Rendón P, Díaz F, Fernández-Gutiérrez C, Martín-Herrera L. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int 2004;24:437-45. [PMID: 15482340 DOI: 10.1111/j.1478-3231.2004.0951.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 504 |
Angeli P. Review article: prognosis of hepatorenal syndrome--has it changed with current practice? Aliment Pharmacol Ther 2004;20 Suppl 3:44-6; discussion 47-8. [PMID: 15335400 DOI: 10.1111/j.1365-2036.2004.02113.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 505 |
Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002;22 Suppl 2:5-13. [PMID: 12220296 DOI: 10.1034/j.1600-0676.2002.00001.x] [Cited by in Crossref: 217] [Cited by in F6Publishing: 190] [Article Influence: 11.4] [Reference Citation Analysis]
|
| 506 |
Moreau R, Lebrec D. Review article: hepatorenal syndrome--definitions and diagnosis. Aliment Pharmacol Ther 2004;20 Suppl 3:24-8; discussion 29-30. [PMID: 15335396 DOI: 10.1111/j.1365-2036.2004.02111.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 507 |
Arroyo V. Review article: hepatorenal syndrome--how to assess response to treatment and nonpharmacological therapy. Aliment Pharmacol Ther 2004;20 Suppl 3:49-54; discussion 55-6. [PMID: 15335402 DOI: 10.1111/j.1365-2036.2004.02114.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 508 |
Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64. [PMID: 15239086 DOI: 10.1002/hep.20262] [Cited by in Crossref: 271] [Cited by in F6Publishing: 236] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 509 |
Alessandria C, Gaia S, Marzano A, Venon WD, Fadda M, Rizzetto M. Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. Eur J Gastroenterol Hepatol 2004;16:607-12. [PMID: 15167164 DOI: 10.1097/00042737-200406000-00015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 510 |
Gonzlez Garca M, Ruiz del rbol Olmos L, Albillos Martnez A. Ascitis y s?ndrome hepatorrenal. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2004;9:504-512. [DOI: 10.1016/s0211-3449(04)70065-x] [Reference Citation Analysis]
|
| 511 |
De Lédinghen V. Traitement du syndrome hépato-rénal. Gastroentérologie Clinique et Biologique 2004;28:130-137. [DOI: 10.1016/s0399-8320(04)95248-7] [Reference Citation Analysis]
|
| 512 |
Kramer L, Druml W. Ascites and intraabdominal infection: . Current Opinion in Critical Care 2004;10:146-51. [DOI: 10.1097/00075198-200404000-00011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 513 |
Duvoux C. Comment traiter un syndrome hépato-rénal. Gastroentérologie Clinique et Biologique 2004;28:270-277. [DOI: 10.1016/s0399-8320(04)95266-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 514 |
Sansoé G, Silvano S, Mengozzi G, Todros L, Smedile A, Touscoz G, Rosina F, Rizzetto M. Inappropriately low angiotensin II generation: a factor determining reduced kidney function and survival in patients with decompensated cirrhosis. J Hepatol 2004;40:417-23. [PMID: 15123355 DOI: 10.1016/j.jhep.2003.11.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 515 |
Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet. 2003;362:1819-1827. [PMID: 14654322 DOI: 10.1016/s0140-6736(03)14903-3] [Cited by in Crossref: 434] [Cited by in F6Publishing: 464] [Article Influence: 22.8] [Reference Citation Analysis]
|
| 516 |
Rössle M, Grandt D. TIPS: an update. Best Pract Res Clin Gastroenterol 2004;18:99-123. [PMID: 15123087 DOI: 10.1016/j.bpg.2003.08.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 517 |
Moreau R. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation. J Hepatol 2004;40:159-61. [PMID: 14672628 DOI: 10.1016/j.jhep.2003.10.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 518 |
Sivayokan T, Dillon JF. Cirrhotic ascites: a review of management. Hospital Medicine 2004;65:22-6. [DOI: 10.12968/hosp.2004.65.1.2414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 519 |
Wong F. Complications of Cirrhosis: Ascites and Spontaneous Bacterial Peritonitis. Atlas of the Liver 2004. [DOI: 10.1007/978-1-4615-6502-4_10] [Reference Citation Analysis]
|
| 520 |
Tran TT, Martin P. Liver Transplantation. Atlas of the Liver 2004. [DOI: 10.1007/978-1-4615-6502-4_14] [Reference Citation Analysis]
|
| 521 |
Vaccaro F, Giorgi A, Riggio O, De Santis A, Laviano A, Rossi-Fanelli F. Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report. Dig Liver Dis 2003;35:503-6. [PMID: 12870738 DOI: 10.1016/s1590-8658(03)00225-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 522 |
Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238-43. [PMID: 12830007 DOI: 10.1053/jhep.2003.50276] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 523 |
Aguillon D, Seguin P, Mallédant Y. [Hepatorenal syndrome: from physiopathology to treatment]. Ann Fr Anesth Reanim. 2003;22:30-38. [PMID: 12738017 DOI: 10.1016/S0750-7658(02)00851-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 524 |
Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver. 2002;22 Suppl 2:5-13. [PMID: 12220296 DOI: 10.1034/j.1600-0676.2002.00001.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 147] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 525 |
Guevara M. [Treatment of hepatorenal syndrome]. Gastroenterol Hepatol 2003;26:270-4. [PMID: 12681123 DOI: 10.1016/s0210-5705(03)70353-7] [Reference Citation Analysis]
|
| 526 |
Gerbes AL, Gülberg V, Ginès P, Decaux G, Gross P, Gandjini H, Djian J; VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-9. [PMID: 12671890 DOI: 10.1053/gast.2003.50143] [Cited by in Crossref: 227] [Cited by in F6Publishing: 241] [Article Influence: 11.4] [Reference Citation Analysis]
|
| 527 |
N/A. N/A. Shijie Huaren Xiaohua Zazhi 2003; 11(3): 330-333 [DOI: 10.11569/wcjd.v11.i3.330] [Reference Citation Analysis]
|
| 528 |
Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003;37:233-43. [PMID: 12540770 DOI: 10.1053/jhep.2003.50084] [Cited by in Crossref: 179] [Cited by in F6Publishing: 153] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 529 |
Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-6. [PMID: 12542598 DOI: 10.1046/j.1440-1746.2003.02934.x] [Cited by in Crossref: 203] [Cited by in F6Publishing: 196] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 530 |
Cárdenas A, Sánchez-fueyo A. Disfunción circulatoria en la cirrosis. Fisiopatología y consecuencias clínicas. Gastroenterología y Hepatología 2003;26:447-455. [DOI: 10.1016/s0210-5705(03)70388-4] [Reference Citation Analysis]
|
| 531 |
Dancygier H, Nagell W. Leberzirrhose und Folgeerkrankungen. Klinische Hepatologie 2003. [DOI: 10.1007/978-3-642-55902-0_27] [Reference Citation Analysis]
|
| 532 |
Cassinello C, Moreno E, Gozalo A, Ortuño B, Cuenca B, Solís-Herruzo JA. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci 2003;48:179-86. [PMID: 12645807 DOI: 10.1023/a:1021763221337] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 533 |
Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38 Suppl 1:S69-89. [PMID: 12591187 DOI: 10.1016/s0168-8278(03)00007-2] [Cited by in Crossref: 196] [Cited by in F6Publishing: 195] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 534 |
Dancygier H. Aszites. Klinische Hepatologie 2003. [DOI: 10.1007/978-3-642-55902-0_19] [Reference Citation Analysis]
|
| 535 |
Prieto M, Clemente G, Casafont F, Cuende N, Cuervas-mons V, Figueras J, Grande L, Herrero J, Jara P, Mas A, de la Matak M, Navasa M. Documento de consenso de indicaciones de trasplante hepático. Gastroenterología y Hepatología 2003;26:355-75. [DOI: 10.1016/s0210-5705(03)70373-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 536 |
Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363-8. [PMID: 12468959 DOI: 10.1097/00042737-200212000-00013] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 537 |
Henriksen JH, Kiszka-Kanowitz M, Bendtsen F. Review article: volume expansion in patients with cirrhosis. Aliment Pharmacol Ther 2002;16 Suppl 5:12-23. [PMID: 12423449 DOI: 10.1046/j.1365-2036.16.s5.3.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 538 |
Briglia AE, Anania FA. Hepatorenal syndrome. Definition, pathophysiology, and intervention. Crit Care Clin 2002;18:345-73. [PMID: 12053838 DOI: 10.1016/s0749-0704(01)00003-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 539 |
Cheng IK. Hepatorenal syndrome. Hong Kong Journal of Nephrology 2002;4:78-86. [DOI: 10.1016/s1561-5413(09)60084-3] [Reference Citation Analysis]
|
| 540 |
Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941-8. [PMID: 12297842 DOI: 10.1053/jhep.2002.35819] [Cited by in Crossref: 375] [Cited by in F6Publishing: 337] [Article Influence: 17.9] [Reference Citation Analysis]
|
| 541 |
Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin JL, Roudot-Thoraval F, Mallat A, Dhumeaux D. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-80. [PMID: 12143045 DOI: 10.1053/jhep.2002.34343] [Cited by in Crossref: 260] [Cited by in F6Publishing: 232] [Article Influence: 12.4] [Reference Citation Analysis]
|
| 542 |
Subramanian RM, Sorrell MF. The hepatorenal syndrome: a continuing challenge. Am J Gastroenterol 2002;97:1868-70. [PMID: 12190146 DOI: 10.1111/j.1572-0241.2002.05896.x] [Reference Citation Analysis]
|
| 543 |
Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002;17:882-8. [PMID: 12164964 DOI: 10.1046/j.1440-1746.2002.02816.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 98] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 544 |
Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 2002;97:2046-50. [PMID: 12190175 DOI: 10.1111/j.1572-0241.2002.05920.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 545 |
Ginès P, Guevara M. Good news for hepatorenal syndrome. Hepatology 2002;36:504-6. [PMID: 12143062 DOI: 10.1053/jhep.2002.35273] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 546 |
Brensing KA, Raab P, Textor J, Görich J, Schiedermaier P, Strunk H, Paar D, Schepke M, Sudhop T, Spengler U, Schild H, Sauerbruch T. Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt: Bonn TIPSS early mortality analysis. Eur J Gastroenterol Hepatol 2002;14:723-31. [PMID: 12169980 DOI: 10.1097/00042737-200207000-00003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 547 |
Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 2002;17:739-47. [PMID: 12121502 DOI: 10.1046/j.1440-1746.2002.02778.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 548 |
Kramer L, Hörl WH. Hepatorenal syndrome. Seminars in Nephrology 2002;22:290-301. [DOI: 10.1053/snep.2002.33670] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 549 |
Arroyo V, Guevara M, Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002;122:1658-76. [PMID: 12016430 DOI: 10.1053/gast.2002.33575] [Cited by in Crossref: 107] [Cited by in F6Publishing: 113] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 550 |
Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-30. [PMID: 11910344 DOI: 10.1053/gast.2002.32364] [Cited by in Crossref: 323] [Cited by in F6Publishing: 345] [Article Influence: 15.4] [Reference Citation Analysis]
|
| 551 |
Cárdenas A, Arroyo V. Hepatorenal syndrome-pathogenesis and treatment. Curr Gastroenterol Rep 2002;4:1-4. [PMID: 11825535 DOI: 10.1007/s11894-002-0029-8] [Reference Citation Analysis]
|
| 552 |
Mullen KD. Treatment of hepatorenal syndrome: lessons from the MARS trial. Hepatology 2002;35:492-3. [PMID: 11826426 DOI: 10.1053/jhep.2002.0350492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 553 |
Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-8. [PMID: 11981339 DOI: 10.1097/00042737-200202000-00009] [Cited by in Crossref: 91] [Cited by in F6Publishing: 84] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 554 |
Dagher L, Moore K. The hepatorenal syndrome. Gut 2001;49:729-37. [PMID: 11600480 DOI: 10.1136/gut.49.5.729] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 555 |
Wongcharatrawee S, Garcia-Tsao G. Clinical management of ascites and its complications. Clin Liver Dis 2001;5:833-50. [PMID: 11565143 DOI: 10.1016/s1089-3261(05)70194-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 556 |
Kim WR. Models predicting the natural history of cirrhosis and need for liver transplantation: . Current Opinion in Organ Transplantation 2001;6:107-13. [DOI: 10.1097/00075200-200106000-00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 557 |
Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH. GUIDELINES FOR THE REFERRAL AND MANAGEMENT OF PATIENTS ELIGIBLE FOR SOLID ORGAN TRANSPLANTATION: . Transplantation 2001;71:1189-204. [DOI: 10.1097/00007890-200105150-00001] [Cited by in Crossref: 152] [Cited by in F6Publishing: 153] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 558 |
Schepke M, Sauerbruch T. Transjugular portosystemic stent shunt in treatment of liver diseases. World J Gastroenterol 2001; 7(2): 170-174 [PMID: 11819756 DOI: 10.3748/wjg.v7.i2.170] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 559 |
Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001;120:726-48. [PMID: 11179247 DOI: 10.1053/gast.2001.22580] [Cited by in Crossref: 303] [Cited by in F6Publishing: 330] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 560 |
Geiger H, Leuschner U. Leberzirrhose und Nierenfunktionsstörungen. Therapie von Leber- und Gallekrankheiten 2001. [DOI: 10.1007/978-3-642-56819-0_32] [Reference Citation Analysis]
|
| 561 |
Carreiro G, Moreira ADL, Murad FF, Azevedo F, Coelho HSM. TIPS - anastomose portossistêmica intra-hepática transjugular. Revisão. Arq Gastroenterol 2001;38:69-80. [DOI: 10.1590/s0004-28032001000100013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 562 |
Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, Uriz J, Quintó L, Ventura PJ, Cárdenas A, Guevara M, Sort P, Jiménez W, Bataller R, Arroyo V, Rodés J. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52. [PMID: 11211907 DOI: 10.1016/s0168-8278(00)00011-8] [Cited by in Crossref: 175] [Cited by in F6Publishing: 175] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 563 |
Anand BS. Drug Treatment of the Complications of Cirrhosis in the Older Adult: . Drugs & Aging 2001;18:575-85. [DOI: 10.2165/00002512-200118080-00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 564 |
Sanyal AJ. The use and misuse of transjugular intrahepatic portasystemic shunts. Curr Gastroenterol Rep. 2000;2:61-71. [PMID: 10981005 DOI: 10.1007/s11894-000-0053-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 565 |
Planas R, Bataller R, Rodés J. Hepatorenal Syndrome. Curr Treat Options Gastroenterol 2000;3:445-50. [PMID: 11096604 DOI: 10.1007/s11938-000-0032-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 566 |
Ginès P. Diagnosis and treatment of hepatorenal syndrome. Baillieres Best Pract Res Clin Gastroenterol 2000;14:945-57. [PMID: 11139348 DOI: 10.1053/bega.2000.0140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 567 |
Stoyanova II, Gulubova MV. Immunocytochemical study on the liver innervation in patients with cirrhosis. Acta Histochem 2000;102:391-402. [PMID: 11145532 DOI: 10.1078/0065-1281-00568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 568 |
Pham PT, Pham PC, Wilkinson AH. The kidney in liver transplantation. Clin Liver Dis 2000;4:567-90. [PMID: 11232162 DOI: 10.1016/s1089-3261(05)70127-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 569 |
Saab S, Han SH, Martin P. Liver transplantation. Selection, listing criteria, and preoperative management. Clin Liver Dis 2000;4:513-32. [PMID: 11232159 DOI: 10.1016/s1089-3261(05)70124-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 570 |
Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-95. [PMID: 10896924 DOI: 10.1136/gut.47.2.288] [Cited by in Crossref: 331] [Cited by in F6Publishing: 294] [Article Influence: 14.4] [Reference Citation Analysis]
|
| 571 |
Eckardt K, Frei U. Reversibility of hepatorenal syndrome in an anuric patient with Child C cirrhosis requiring haemodialysis for 7 weeks. Nephrology Dialysis Transplantation 2000;15:1063-5. [DOI: 10.1093/ndt/15.7.1063] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 572 |
Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Löhr JM, Liebe S, Emmrich J, Korten G, Schmidt R. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-86. [PMID: 10827226 DOI: 10.1002/lt.500060326] [Cited by in Crossref: 16] [Cited by in F6Publishing: 98] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 573 |
Bataller R, Ginès P, Arroyo V, Rodés J. Hepatorenal syndrome. Clin Liver Dis 2000;4:487-507. [PMID: 11232202 DOI: 10.1016/s1089-3261(05)70120-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 574 |
Dagher L, Patch D, Marley R, Moore K, Burroughs A. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther 2000;14:515-21. [PMID: 10792112 DOI: 10.1046/j.1365-2036.2000.00740.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 575 |
Cantley L, Joannidis M. Kidney and Electrolyte Disturbances. Handbook of Alcoholism 2000. [DOI: 10.1201/9781420036961.ch19] [Reference Citation Analysis]
|
| 576 |
Wong F, Blendis L. Hepatorenal failure. Clin Liver Dis 2000;4:169-89. [PMID: 11232183 DOI: 10.1016/s1089-3261(05)70102-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 577 |
Gatta A, Bolognesi M. Pathophysiology of Portal Hypertension. Portal Hypertension 2000. [DOI: 10.1007/978-3-642-57116-9_1] [Reference Citation Analysis]
|
| 578 |
Phillips MG, Harry R, Wendon J. The Hepatorenal Syndrome. Yearbook of Intensive Care and Emergency Medicine 2000. [DOI: 10.1007/978-3-662-13455-9_34] [Reference Citation Analysis]
|
| 579 |
Uriz J. Ascitis cirrótica. Fisiopatología, métodos diagnósticos y síndrome hepatorrenal. Medicine - Programa de Formación Médica Continuada Acreditado 2000;8:493-501. [DOI: 10.1016/s0304-5412(00)70096-5] [Reference Citation Analysis]
|
| 580 |
Cardellach F, Ginès Rolando Ortega P, Ortega R, Uriz J. Síndrome hepatorrenal: nuevos aspectos fisiopatológicos y terapéuticos. Medicina Clínica 2000;115:549-557. [DOI: 10.1016/s0025-7753(00)71620-4] [Reference Citation Analysis]
|
| 581 |
Gentilini P, Laffi G, La Villa G, Romanelli RG, Blendis LM. Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication? J Hepatol 1999;31:1088-97. [PMID: 10604585 DOI: 10.1016/s0168-8278(99)80324-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 582 |
Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999;30:870-5. [PMID: 10498636 DOI: 10.1002/hep.510300430] [Cited by in Crossref: 138] [Cited by in F6Publishing: 115] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 583 |
Ginès P, Arroyo V. Hepatorenal Syndrome. JASN 1999;10:1833-9. [DOI: 10.1681/asn.v1081833] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 584 |
Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7. [PMID: 10347109 DOI: 10.1002/hep.510290629] [Cited by in Crossref: 381] [Cited by in F6Publishing: 334] [Article Influence: 15.9] [Reference Citation Analysis]
|
| 585 |
Keeffe EB. Patient selection and listing policies for liver transplantation. J Gastroenterol Hepatol 1999;14 Suppl:S42-7. [PMID: 10382638 DOI: 10.1046/j.1440-1746.1999.01876.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 586 |
Deschênes M, Dufresne MP, Bui B, Fenyves D, Spahr L, Roy L, Lafortune M, Pomier-Layrargues G. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol 1999;94:1361-5. [PMID: 10235219 DOI: 10.1111/j.1572-0241.1999.01112.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 587 |
Rincón AR, Covarrubias A, Pedraza-chaverrí J, Poo JL, Armendáriz-borunda J, Panduro A. Differential effect of CCl4 on renal function in cirrhotic and non-cirrhotic rats. Experimental and Toxicologic Pathology 1999;51:199-205. [DOI: 10.1016/s0940-2993(99)80094-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 588 |
Pape GR, Sauerbruch T. Leberkrankheiten. Therapie innerer Krankheiten 1999. [DOI: 10.1007/978-3-662-10477-4_42] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 589 |
Butt AK, Khan AA, Alam A, Shah SW, Shafqat F, Naqvi AB. Predicting hospital mortality in cirrhotic patients: comparison of Child-Pugh and Acute Physiology, Age and Chronic Health Evaluation (APACHE III) scoring systems. Am J Gastroenterol 1998;93:2469-75. [PMID: 9860411 DOI: 10.1111/j.1572-0241.1998.00706.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 590 |
Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, Kneteman NM, Lake JR, Martin P, Rakela J. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation. 1998;66:956-962. [PMID: 9798717 DOI: 10.1097/00007890-199810150-00034] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 591 |
Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, Lebrec D. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70. [PMID: 9824265 DOI: 10.1016/s0168-8278(98)80151-7] [Cited by in Crossref: 150] [Cited by in F6Publishing: 162] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 592 |
Schrier RW, Fassett RG, Ohara M, Martin P. Pathophysiology of renal fluid retention. Kidney International 1998;54:S127-32. [DOI: 10.1046/j.1523-1755.1998.06724.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 593 |
Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol 1998;29:328-41. [PMID: 9722218 DOI: 10.1016/s0168-8278(98)80022-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 105] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 594 |
Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodés J. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-22. [PMID: 9696006 DOI: 10.1002/hep.510280219] [Cited by in Crossref: 280] [Cited by in F6Publishing: 239] [Article Influence: 11.2] [Reference Citation Analysis]
|
| 595 |
González E, Rimola A, Navasa M, Andreu H, Grande L, García-Valdecasas JC, Cirera I, Visa J, Rodés J. Liver transplantation in patients with non-biliary cirrhosis: prognostic value of preoperative factors. J Hepatol 1998;28:320-8. [PMID: 9514545 DOI: 10.1016/0168-8278(88)80020-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 596 |
McGuire BM, Bloomer JR. Complications of cirrhosis. Why they occur and what to do about them. Postgrad Med 1998;103:209-12, 217-8, 223-4. [PMID: 9479317 DOI: 10.3810/pgm.1998.02.361] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 597 |
Arroyo V, Sort P, Ginés P. The kidney in liver disease. Critical Care Nephrology 1998. [DOI: 10.1007/978-94-011-5482-6_78] [Reference Citation Analysis]
|
| 598 |
Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez W, Arroyo V, Rodés J. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41. [PMID: 9425914 DOI: 10.1002/hep.510270107] [Cited by in Crossref: 234] [Cited by in F6Publishing: 243] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 599 |
Jalan R, Hayes PC. Hepatic encephalopathy and ascites. Lancet 1997;350:1309-15. [PMID: 9357420 DOI: 10.1016/S0140-6736(97)07503-X] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 600 |
Jenkins SA, Shields R, Davies M, Elias E, Turnbull AJ, Bassendine MF, James OF, Iredale JP, Vyas SK, Arthur MJ, Kingsnorth AN, Sutton R. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997;41:526-33. [PMID: 9391254 DOI: 10.1136/gut.41.4.526] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 601 |
D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 1997;11:243-56. [PMID: 9395746 DOI: 10.1016/s0950-3528(97)90038-5] [Cited by in Crossref: 160] [Cited by in F6Publishing: 164] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 602 |
Wong F, Girgrah N, Blendis L. Review: the controversy over the pathophysiology of ascites formation in cirrhosis. J Gastroenterol Hepatol 1997;12:437-44. [PMID: 9195401 DOI: 10.1111/j.1440-1746.1997.tb00463.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 603 |
Ginès P, Fernández-Esparrach G, Arroyo V. Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment. Baillieres Clin Gastroenterol 1997;11:365-85. [PMID: 9395753 DOI: 10.1016/s0950-3528(97)90045-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 604 |
Ginès P, Arroyo V, Rodès J. Pathophysiology, complications, and treatment of ascites. Clin Liver Dis 1997;1:129-55. [PMID: 15562674 DOI: 10.1016/s1089-3261(05)70261-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 605 |
Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997;349:697-8. [PMID: 9078203 DOI: 10.1016/s0140-6736(97)24010-9] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 606 |
Saló J, Ginès A, Quer JC, Fernández-Esparrach G, Guevara M, Ginès P, Bataller R, Planas R, Jiménez W, Arroyo V, Rodés J. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996;25:916-23. [PMID: 9007721 DOI: 10.1016/s0168-8278(96)80297-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 607 |
Roberts LR, Kamath PS. Ascites and hepatorenal syndrome: pathophysiology and management. Mayo Clin Proc 1996;71:874-81. [PMID: 8790265 DOI: 10.4065/71.9.874] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 608 |
Kelley SD. Scenario number one: Discussant-Kelley. Liver Transpl 1996;2:72-77. [DOI: 10.1002/lt.500020114] [Reference Citation Analysis]
|
| 609 |
Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-76. [PMID: 8550036 DOI: 10.1002/hep.510230122] [Cited by in Crossref: 1081] [Cited by in F6Publishing: 1116] [Article Influence: 40.0] [Reference Citation Analysis]
|
| 610 |
Simpson KJ, Finlayson ND. Clinical evaluation of liver disease. Baillieres Clin Gastroenterol 1995;9:639-59. [PMID: 8903798 DOI: 10.1016/0950-3528(95)90054-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 611 |
Hsia HC, Lin HC, Tsai YT, Lee FY, Hwang CC, Hou MC, Lee SD. The effects of chronic administration of indomethacin and misoprostol on renal function in cirrhotic patients with and without ascites. Scand J Gastroenterol 1995;30:1194-9. [PMID: 9053973 DOI: 10.3109/00365529509101630] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 612 |
Tsai YT, Lin HC, Yang MC, Lee FY, Hou MC, Chen LS, Lee SD. Plasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function. J Hepatol 1995;23:681-8. [PMID: 8750167 DOI: 10.1016/0168-8278(95)80034-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 613 |
Martin P, Schrier RW. Renal Sodium Excretion and Edematous Disorders. Endocrinology and Metabolism Clinics of North America 1995;24:459-79. [DOI: 10.1016/s0889-8529(18)30027-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 614 |
Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995;19:635-41. [PMID: 7573786 DOI: 10.1111/j.1530-0277.1995.tb01560.x] [Cited by in Crossref: 158] [Cited by in F6Publishing: 155] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 615 |
Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Büttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 1995;17:135-46. [PMID: 7644764 DOI: 10.3109/08860229509026250] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 616 |
Abuelo JG. Vascular causes of renal failure. Renal Failure 1995. [DOI: 10.1007/978-94-011-0047-2_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 617 |
Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodés J. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-501. [PMID: 7982650 DOI: 10.1002/hep.1840200619] [Cited by in Crossref: 382] [Cited by in F6Publishing: 382] [Article Influence: 13.2] [Reference Citation Analysis]
|
| 618 |
Castells A, Saló J, Planas R, Quer JC, Ginès A, Boix J, Ginès P, Gassull MA, Terés J, Arroyo V. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994;20:584-91. [PMID: 8076916] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 619 |
Craig RM. Precision in nutritional diagnoses. Gastroenterology 1993;105:1923. [PMID: 8253374 DOI: 10.1016/0016-5085(93)91103-o] [Reference Citation Analysis]
|
